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ABSTRACT 
 
A Structural and Kinetic Study into the Role of the Quaternary Shift in Bacillus 
stearothermophilus Phosphofructokinase.   
(August 2010) 
Rockann Elizabeth Mosser, B.S., The University of Texas at Austin 
Chair of Advisory Committee:  Dr. Gregory D. Reinhart 
 
 Bacillus stearothermophilus phosphofructokinase (BsPFK) is a homotetramer 
that is allosterically inhibited by phosphoenolpyruvate (PEP), which binds along one 
dimer-dimer interface.  The substrate, fructose-6-phosphate (F6P), binds along the other 
dimer-dimer interface.  The different functional forms BsPFK can take when in the 
presence of F6P and PEP can be described by the following diproportionation 
equilibrium: 
XE + EA ↔ XEA + E 
where XE is the enzyme bound to PEP, EA is the enzyme bound to F6P, E represents the 
apo enzyme, and XEA is the ternary complex formed when both substrate and inhibitor 
are bound.  Currently in the Protein Data Bank (PDB) there are two relevant forms of 
wild-type BsPFK, the EA form and the X‟E form, which represents the enzyme bound to 
the PEP analog, phosphoglycolate (PGA).  When comparing the EA and the X‟E 
structures, a 7° rotation about the substrate-binding interface is observed and is termed 
the quaternary shift.  The current study uses methyl TROSY NMR to examine the 
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different liganded states of BsPFK, and for the first time structural data for the XEA 
species is shown.  In addition, crystallography was used to obtain the first apo structure 
of BsPFK.  To distinguish between changes associated with the quaternary shift and 
those associated with the intra-subunit tertiary changes, the variant D12A BsPFK was 
studied using kinetics, crystallography, and NMR.  Crystal structures of apo and PEP 
bound forms of D12A BsPFK both indicate a shifted structure similar to the X‟E form of 
wild-type.  Kinetic studies of D12A BsPFK, when compared to wild-type, show a 50-
fold diminished F6P binding affinity, 100-fold enhanced binding affinity, and a similar 
coupling constant.  A conserved hydrogen bond between D12 and T156 takes place 
across the substrate binding interface in the EA form of BsPFK.  The variant T156A 
BsPFK shows similar binding, coupling, and structural characteristics to D12A BsPFK.  
PEP still inhibits these variants of BsPFK despite the fact that the enzymes are in the 
quaternary shifted position prior to PEP binding.  Therefore the quaternary shift of 
BsPFK primarily perturbs ligand binding but does not directly contribute to heterotropic 
allosteric inhibition.   
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NOMENCLATURE 
BCA   Bicinchoninic Acid  
BsPFK  Phosphofructokinase from Bacillus stearothermophilus 
DTT   Dithiothreitol 
EcPFK  Phosphofructokinase from Escherichia coli  
EDTA  Ethylenediamine Tetraacetic Acid  
EPPS   N- [2-Hydroxyethyl] Piperazine-N‟-3-Propanesulfonic Acid 
F16BP  Fructose-1, 6-Bisphosphate 
F6P   Fructose-6-Phosphate 
LB   Lysogeny Broth  
LbPFK Phosphofructokinase from Lactobacillus delbrueckii 
MOPS  3-[N-Morpholino] Propanesulfonic acid 
NADH  Nicotinamide Adenine Dinucleotide, reduced form 
PAGE   Polyacrylamide Gel Electrophoresis  
PEP  Phosphoenolpyruvate 
PDB  Protein Data Bank 
PFK  Phosphofructokinase  
PGA   Phospoglycolate 
SDS   Sodium Dodecyl Sulfate  
Tris   Tris [Hyroxymethyl] Aminomethane 
𝐾𝑖𝑎
°   Dissociation constant for A in the absence of effector 
𝐾𝑖𝑎
∞    Dissociation constant for A in the saturating presence of effector 
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𝐾𝑖𝑥
°   Dissociation constant for X in the absence of substrate 
𝐾𝑖𝑥
∞   Dissociation constant for X in the saturating presence of substrate 
ε   Extinction coefficient  
[A]   Concentration of substrate  
[E]   Concentration of enzyme  
[ES]   Concentration of enzyme substrate complex  
ΔG   Coupling free energy of entire reaction 
𝛿G  Coupling free energy of individual components 
Qax   Coupling constant between substrate and effector 
[S]   Concentration of substrate 
v  Initial velocity  
V
max   
Maximal velocity 
[X]  Concentration of effector 
  
ix 
 
 
TABLE OF CONTENTS 
              Page 
ABSTRACT ..............................................................................................................  iii 
DEDICATION ..........................................................................................................  v 
ACKNOWLEDGEMENTS ......................................................................................  vi 
NOMENCLATURE ..................................................................................................  vii 
TABLE OF CONTENTS ..........................................................................................  ix 
LIST OF FIGURES ...................................................................................................  xi 
LIST OF TABLES ....................................................................................................  xiii 
CHAPTER 
I      INTRODUCTION: A HISTORY OF OUR UNDERSTANDING OF 
ALLOSTERIC ENZYMES…………………………………………… 1 
   
The Discovery of Proteins and Catalysis………………………..… 2 
 Fermentation………………………………………………………. 5 
 Zymase and Oxidase…………………………………………....…. 10 
 Enzyme Kinetics…………………………………………………... 12 
 Hemoglobin………………………………………………………... 18 
 Classification of Enzymes as Protein……………………………… 20 
 Enzyme Regulation………………………………………………… 22 
 Allostery Theory……………………………………………………. 24
 Allostery and Kinetics……………………………………………… 27 
 The Present Study…………………………………………………... 33 
 
 II STRUCTURE OF THE APO FORM OF BACILLUS 
STEAROTHERMOPHILUS PHOSPHOFRUCTOKINASE…………… 35 
   
   Materials and Methods……………………………………………… 39 
   Results………………………………………………………………. 42 
   Discussion…………………………………………………………... 52 
 
 III REDEFINING THE ROLE OF THE QUATERNARY SHIFT IN  
  BACILLUS STEAROTHERMOPHILUS 
PHOSPHOFRUCTOKINASE………………………………………….. 57 
x 
 
 
CHAPTER   Page 
 
   Materials and Methods……………………………………………… 65 
   Results………………………………………………………………. 73 
   Discussion…………………………………………………………... 90 
   Conclusion………………………………………………………….. 95 
 
 IV A SOLUTION NMR STUDY OF BACILLUS  
  STEAROTHERMOPHILUS PHOSPHOFRUCTOKINASE..………… 96 
 
   Materials and Methods………………………………….………… 100 
   Results…………………………………………………………….. 105 
   Discussion………………………………………………………… 114 
 
 V  SUMMARY…………………………………………………………… 118 
 
REFERENCES…………………………………………………………………….. 124 
 
VITA………………………………………………………………………………. 142 
 
  
xi 
 
 
LIST OF FIGURES 
FIGURE   Page 
 1-1  Single substrate-single modifier scheme…………………………… 28 
 2-1  Apo BsPFK tetramer………………………………………………... 44 
 2-2  Comparison of wild-type BsPFK crystal structures………………... 46 
 2-3  Comparison of wild-type BsPFK B-factors………………………... 47 
 2-4  Overlay of residues in the Fru-6-P binding site of BsPFK………… 49 
 2-5  Overlay of residues in the effector binding site of BsPFK………… 51 
 3-1  Crystal structure of D12 region in wild-type BsPFK………………. 61 
 3-2  Comparison of the D12 region between wild-type and variants of  
    BsPFK crystal structures…………………………………………… 64 
 
 3-3  Specific activity versus F6P concentration for wild-type and D12A 
BsPFK……………………………………………………………… 75 
 
 3-4  Specific activity versus F6P concentration under first-order  
    conditions for wild-type and D12A BsPFK………………………... 76 
 
 3-5  K vs. PEP concentration plot comparing Km/Vmax and K1/2 methods  
    for wild-type BsPFK………………………………………………... 78 
 
 3-6  Influence of PEP on the Km/Vmax of wild-type, D12A, and H160A 
    BsPFKs……………………………………………………………… 79 
 
 3-7  Influence of PEP on K1/2 for F6P of wild-type, T156A, T158A, and  
    S159A BsPFKs………………………………………………………. 81 
 
 3-8  Electron density map showing the electron cloud fitting PEP that is  
   bound in the effector binding site in D12A BsPFK…………………. 84 
 
 3-9  Overlay of residues in the effector binding site of D12A BsPFK…… 87 
 3-10  Overlay of residues in the effector binding site for inhibitor bound  
   BsPFK……………………………………………………………….. 87 
 
xii 
 
 
FIGURE   Page 
 3-11  Comparison of the variant BsPFK B-factors……………………… 89 
 4-1  Apo BsPFK with the isoleucines highlighted……………………… 106 
 4-2  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild- 
   type BsPFK………………………………………………………… 108 
 
 4-3  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild- 
   type BsPFK compared with wild-type BsPFK ternary complex…… 110 
 
 4-4  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled D12A  
   BsPFK………………………………………………………………. 111 
 
 4-5  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild- 
   type and D12A BsPFK……………………………………….……. 112 
  
 4-6  Structure of the α-ketobutyrate precursor added to the minimal  
   media, and how each component of the media is incorporated into  
   the end product isoleucine………………………………………….    115 
 
  
xiii 
 
 
LIST OF TABLES 
 
TABLE   Page 
 2-1  Table 2-1  Data collection and refinement statistics…………….… 43 
 3-1  Data collection and refinement statistics for apo and PEP bound  
   D12A BsPFK structures…………………………………………… 70 
 
 3-2  Steady-state kinetic and coupling parameters for wild-type, D12A,  
   and H160A BsPFKs……………………………………………….. 80 
 
 3-3  Steady-state kinetic and coupling parameters for variant BsPFKs… 80 
 4-1  Cross-peak coordinates and signal/noise data for unique cross- 
   peaks in NMR spectra……………………………………………… 107
  
 
 
1 
 
 
CHAPTER I 
INTRODUCTION:  A HISTORY OF OUR UNDERSTANDING OF ALLOSTERIC 
ENZYMES 
 
 This review attempts to follow the development of discoveries and ideas that 
have led us to our current understanding of allosteric enzymes.  The most apparent 
theme realized while researching this article is the fact that every concept, every 
experiment, and every theory relies on a previously established concept, experiment, or 
theory, and it is through the written word that scientists are able to pass their research on 
to the current and next generations.  The foundations of the modern scientific method 
can be traced to a treatise written in 1637 by Rene Descartes (1).  Descartes enlightened 
the scientific community to the advantages of treating science as a method, and soon 
after, the first scientific publications started to appear.  The advent of scientific 
publications during the mid to late 17
th
 century propagated the emergence of modern 
science, a body of work that grew exponentially.  In 1700, only 35 years after the first 
scientific publication appeared, there were 30 scientific journals in existence, and in 
1800 several hundred existed.  Today, there is an estimated 15,000 journals world-wide 
with a staggering one to two million articles published every year (2).  With this in mind, 
a thorough and complete discourse of allosteric enzymes cannot be made without 
examining the beginnings of our understanding of proteins, enzymes, and kinetics. 
___________ 
This dissertation follows the style of Biochemistry. 
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The Discovery of Protein and Catalysis 
The very first description of a protein can be traced back to a communication of 
Iacopo B. Beccari made in 1745, where he separated and identified gluten and starch 
from wheat flour.  Beccari classified gluten as being an animal substance, and starch as 
being a vegetable substance.  He theorized that gluten was an animal component of the 
plant which animals used as building blocks for their tissues (3, 4).  In 1774, Hilaire M. 
Rouelle named the glutinous material Beccari had discovered “vegeto-animal matter” 
when he realized that the substance was not confined to flour and had a lot in common 
with casein from milk (5, 6).  Later, in 1789, Giovanni V. M. Fabbroni wrote a memoir 
connecting the action of fermentation with the “vegeto-animal matter” (7).  In his 
memoir, Fabbroni describes, “the material which decomposes sugar in vinous 
effervescence is the vegeto-animal substance.” (6, 7).   
The “vegeto-animal matter” was later given the name “protein” around the year 
1838.  The Dutch scientist, Gerhardus J. Mulder, and the Swedish chemist, Jöns Jacob 
Berzelius, wrote numerous letters to each other concerning the nature of the “vegeto-
animal matter” (8).  Mulder, under the advisement of Berzelius, analyzed the “vegeto-
animal” substance present in blood, silk, egg whites, and plants and realized that all of 
the materials contained carbon, hydrogen, nitrogen, and oxygen in the same ratio: C400, 
H620, N100, O120.  He also found a very small percentage of phosphorous and sulfur in all 
of the samples (9).  Berzelius was impressed with the quantity of oxygen present in the 
material and wrote a letter to Mulder where he said: 
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The name protein that I propose to you for the organic oxide of fibrin and 
albumin I wish to derive from πρωηείοζ [primarius] because it appears to 
be the primary or principal substance of animal nutrition which the plants 
prepare for the herbivores, and which these then supply to the carnivores 
(10). 
Mulder wrote two papers, one in 1838 and one in 1839, where he presented his findings 
along with the proposal of the new name for the “vegeto-animal material” (9, 11).  Since 
Mulder was the first to publish the word “protein”, he is often incorrectly credited with 
deriving the word.   
One of the first descriptions of the action of an enzyme was published in 1810 by 
Louis Planche.  In this paper, Planche describes an intense blue color that occurred when 
he added a small piece of horseradish root to a tincture of guaiacum (12) (guaiacum is a 
flowering plant that was often used to treat syphilis).  Later, in 1820, Planche followed 
up on his previous observations by proving that the color change was not due to light or 
air exposure, as was previously hypothesized, but rather was a property of a substance in 
horseradish root (13).  As a result, Planche is credited with being the first to discover 
horseradish peroxidase, and, more importantly, to provide the first description of an 
enzyme in the literature.   
 One of the first papers to describe an enzyme isolate was written by a pair of 
French chemists in 1833.  Anselme Payen and Jean F. Persoz isolated a water-soluble, 
amorphous substance from malt barley that broke down starch into dextrose and maltose 
(14).  They were interested in using this substance, which they named diastase (meaning 
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to separate), for use in the sugar and starch industries.  Many subsequent papers used the 
word “diastase” or the suffix –ase to describe the component that was responsible for 
what we now know is enzyme action.  Therefore, it appears to be happenstance that the 
suffix –ase was adopted as the suffix used for naming enzymes.   
 By the early 1800‟s, it was known that digestion was caused by something in 
addition to hydrochloric acid.  In 1834, Johannes Müller studied the report given by 
Payen and Persoz and concluded that the unknown component of digestion may be 
related to diastase. With the help of his assistant, Theodor Schwann, he was able to 
confirm the presence of a catalytic component in gastric fluid that facilitated digestion.  
Schwann concluded, “the digestive principle is characterized as an individual substance, 
to which I have given the name pepsin.” (15). 
 Catalysis was a very novel concept for Schwann and Müller to use in their paper.  
In fact,   the words “catalytic” and “catalysis” were coined by Berzelius earlier in the 
same year that Schwann‟s paper was published.  Berzelius stated, “The catalytic force 
appears to consist intrinsically in this: that bodies through their mere presence, and not 
through their affinity, may awaken affinities slumbering at this temperature.” (6, 16).  
Berzelius defined catalysis through the use of several examples, one of which was 
diastase.  Even though his definition of catalysis was not accurate; he is the first to 
recognize the process.  He concluded that there are “thousands of catalytic processes” 
that occur in plants and animals, and he predicted that some day in the future we will 
understand the “catalytic force” in the body (16). 
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Fermentation 
Enzyme action was an unknown and unfathomable concept in the early 19
th
 
century.  It is to extensive research mostly on fermentation, but also digestion and 
putrefaction, that we owe the majority of our understanding of enzyme action.  
Therefore, a comprehensive description of how the concept of enzymes evolved must 
include a review on fermentation.  Since fruits ferment naturally, mankind was 
manipulating the fermentative process long before recorded history began.  The study of 
fermentation lead to some of the most formidable disagreements between scientists of 
the 19
th
 century, and fueled some amazingly intuitive research into the foundations of 
enzymology.   
As stated previously, Fabbroni may have been the first to postulate that it was the 
action of “glutens” with sugars that caused fermentation to occur (7).  Unlike Fabbroni, 
who was very specific as to the nature of what caused fermentation, Louis J.  Thenard 
was more cautious in his remarks. Thenard knew that yeasts were needed for 
fermentation to occur, although he didn‟t know how.  He asked in his 1803 paper “What 
is the nature of this body?  How does it act on the sugar?” (6, 17).  He described the 
fermentative agent as a “ferment” and performed several tests he used to show that the 
ferment was of animal nature.   
During the 1830‟s, as a testament to the controversial nature of the subject, there 
was an explosion of papers over whether or not fermentation (and presumably digestion 
and putrefaction) was a purely chemical mechanism or if it was a mixture of biological 
and chemical processes.  With the emergence of microscopes that could magnify over 
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400 times, the microscopic world of the yeast cell was being uncovered.  Papers written 
between 1837 and 1838 by Charles Cagniard-Latour, Theodor Schwann, and Friedrich 
T. Kützing supported the view that fermentation was a biological process that was 
caused by a living organism.  Cagniard-Latour studied yeast using a microscope and a 
micrometer, which allowed him to measure the “globules”.  He concluded that yeast 
were able to reproduce themselves, which meant they were living, but they did not move 
on their own, which meant they belonged to the plant kingdom (18).  Schwann suspected 
that the ferment was living, so he tried several types of poisons on the yeasts.  He 
surmised (which was supported by Professor Franz F. Meyen, a German botanist and 
plant physiologist) that the yeast ferment was a fungus and not a plant due to the lack of 
green pigment (19).  In the same paper, Schwann stated,  
Wine fermentation must be a decomposition that occurs when the sugar-
fungus uses sugar and nitrogenous substances for growth, during which, 
those elements not so used are preferentially converted to alcohol.(19, 
20). 
Independently, Kützing made similar observations to those of Cagniard-Latour and 
Schwann and he knowingly published his redundant findings. Kützing felt that his paper 
had a few facts about ferments that were not discussed previously and he concluded that 
yeasts were not chemical compounds, but organic bodies or organisms (6, 21).   
Among the most vocal opponents to the concept of yeast being a living organism 
were Jöns Berzelius, Justus von Liebig, and Friedrich Wöhler.  These chemists were 
probably the most influential chemists of their day, and the fact that they opposed so 
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vehemently the research findings of Cagniard-Latour, Schwann, and Kützing slowed the 
advancement of microbiology.  On the other hand, enzymology owes its emergence to 
the interpretation of fermentation as being a purely catalytic chemical force.  The debate 
over whether or not yeasts/ferments were alive grew to ridiculous, if not humorous 
proportions.  Liebig and Wöhler went so far as to publish an anonymous skit in their 
journal that ridiculed the microscopic findings of Cagniard-Latour, Schwann, and 
Kützing.  The parody was titled, “The riddle of alcoholic fermentation solved” and 
related yeast to a distilling apparatus, where the yeast ate sugar and excreted alcohol 
from an anus and carbonic acid from its genitals (20, 22).  Liebig wrote in his 1839 
paper that ferments were internally unstable and transferred this instability to the sugar 
being fermented.  He also believed that yeast were not alive, but were non-crystalline 
globular solids that precipitated from the solution undergoing fermentation (23).  
Berzelius believed that fermentation was a purely chemical phenomenon that occurred 
via catalysis and that yeasts were no more alive than a precipitate of alumina (24).  He 
attacked Schwann‟s work by saying “his [Schwann‟s] experiments were worthless and 
his conclusions exhibited a frivolity which had long been banished from science.” (20, 
25).  Almost twenty years later, in 1858, Moritz Traube entered the fray when he wrote 
that ferments were “definite chemical compounds arising from the reaction of protein 
substances with water”.  Traube did not think yeasts were alive, but he believed that 
ferments were proteins, which made him one of the first to relate fermentation to 
proteins (6, 26). 
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The question over whether or not fermentation was achieved by a living 
organism was finally laid to rest in 1861 by Louis Pasteur.  Pasteur performed 
experiments that proved yeast were in fact cellular life.  Pasteur proved that yeasts 
behaved like plants in the presence of oxygen and like ferments in the absence of oxygen 
(6, 27).  With this question finally answered, another controversy soon became evident 
in the literature.  The question was if processes such as fermentation occurred in the 
presence or absence of living organisms.  The two major contributors to the argument 
were Pasteur and Pierre Berthelot, both of whom openly attacked the other‟s work.  
Pasteur believed in the vital force of living organisms.  Vital force, or vitalism, is the 
belief that living entities have some fluid or spirit in them that makes them alive, and 
thusly different from inanimate things.  Pasteur held firm to the idea that fermentation 
(and other reactions such as putrefaction and digestion) could only be achieved inside 
living organisms, and that the chemical reactions that are carried out inside living cells 
could not be separated from the living nature of the organism.  Berthelot, on the other 
hand, believed that actions such as fermentation could occur outside of a living being.   
A public debate that occurred between Pasteur and Berthelot revolved around the 
actions of what Berthelot named invertase.  The invertase that Berthelot used was 
composed of a crude yeast lysate which hydrolyzed sucrose into a mixture of fructose 
and glucose (aka inverted sugar).  Invertase got its name because the conversion of 
sucrose into inverted sugar manifests itself by an inversion of polarized light.  In 1869, 
Pasteur argued that the formation of inverted sugar was “only an incidental 
phenomenon” that occurred due to the production of succinic acid.  Succinic acid is 
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produced during fermentation; and Pasteur knew that acids inverted sucrose; therefore, 
Pasteur argued that it was the succinic acid and not invertase that inverted sucrose (20, 
28).  During the same year, Berthelot published the results of the following experiments.  
Berthelot prepared a cell free extract of invertase, and proceeded to set up three 
solutions, all of which contained a fixed amount of sucrose.  To solution A he added 
succinic acid, in an amount that far exceeded that which is normally produced by yeast 
cells during fermentation.  To solution B he added his preparation of invertase, and to 
solution C he added invertase and sodium bicarbonate.  He showed that solution A 
produced a minute amount of inverted sugar, while both solutions B and C (which 
contained the invertase) produced substantial amounts of inverted sugar.  Berthelot 
concluded “It is not to succinic acid that one must attribute the inversion which follows 
the yeast‟s action…These facts prove that beer yeast inverts cane sugar by its own action 
and independently of the acidity of the solution.”(20, 29).  Berthelot believed that it was 
the excreted “ferments” of cells that caused enzyme action, and that the cell itself did not 
necessarily act on the sugar (in the case of fermentation).  Pasteur was not convinced by 
Berthelot‟s experiments and rebutted immediately with another paper which argued over 
semantics rather than the science, as he felt that his definition of a ferment was 
fundamentally different from Berthelot‟s definition (20, 30).   
At this time, whole yeast cells and yeast extracts were often called “ferments”, 
interchangeably.  More specifically, ferments that performed enzyme action within cells 
were called formed or organized ferments, and ferments that acted in the absence of 
cellular life were called unformed or unorganized ferments.  The word “enzyme” was 
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introduced in 1876 by Wilhelm Kühne in an attempt to differentiate between the two 
types of ferments.  He suggested that the term “ferment” would be used to describe the 
organized ferments and the term “enzyme” would describe the chemical component that 
performed catalysis and functioned outside of the living cell (31, 32).  “Enzyme” is a 
Greek word meaning “in yeast” or “in leaven”, and is meant to reflect that fermentation 
is a process performed by a component that is found in yeast (6).   
 
Zymase and Oxidase 
The controversy headed up by Pasteur and Berthelot was finally laid to rest by 
the experiments of Eduard Buchner in 1897.  Buchner had been working for years on a 
method of obtaining the cellular components of the yeast cell without damaging them.  
Finally, he was able to extract the “yeast juice” from the cells through a method that 
combined grinding and pressing the cells.  Buchner added sugar to the extract in an 
effort to preserve it, and he recognized the ensuing fermentation that took place (6).   In 
his publication he described how to prepare a cell free yeast extract capable of 
fermentation (33).  Buchner wrote: 
Up to now, the following conclusions have to be drawn for the theory of 
fermentation.  First, it is proved that to bring about the fermentation 
process, such a complicated apparatus as represented by the yeast cell is 
not required.  It is considered that the bearer of the fermenting action of 
the press juice is more truly a dissolved substance, doubtless a protein; 
this will be designated as zymase (6, 33).  
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He believed that zymase was a single molecule that converted sugar into alcohol and 
carbon dioxide.  Buchner did not think that zymase was an enzyme since it was a wide 
held belief, at that time, that enzymes were capable of performing only simple reactions.  
In fact, all known enzymes at the time were hydrolytic agents; therefore, all enzyme 
actions were assumed to partake in hydrolysis.    
The discovery of zymase was a critical turning point in our understanding of 
enzymes, even though the fundamental comprehension of zymase was wrong.  A new 
concept was evolving that regarded enzymes as functional catalysts that could reside 
both inside and outside of living cells.  A new understanding of enzymes was emerging 
that owed its beginnings to the findings of Buchner and the realization that enzymes 
carried out reactions other than hydrolysis, such as oxidation and synthesis. 
Gabriel Bertrand discovered the first oxidase in 1895 when he was trying to 
understand how the black lacquer finish, used by the ancient Chinese furniture makers, 
worked (34).  He studied the latex from the Vietnamese lac tree and found that in order 
to get a good black finish; the latex had to be maintained in a very humid environment. 
Bertrand hypothesized that oxidation was occurring and that a water soluble enzyme 
may be involved.  He was expecting a hydrolytic enzyme to be the culprit; however, he 
found that the enzyme in the latex, which he named “laccase”, actually caused uptake of 
oxygen by several substrates (34, 35).  A few years later, in 1897, Bertrand showed that 
the activity of laccase depended on the presence of the manganese ion (36).  The 
manganese ion was not a substrate, but a cofactor; therefore, Bertrand was the first to 
discover enzyme cofactors.  In 1906, Arthur Harden and William J. Young expanded on 
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Buchner‟s and Bertrand‟s discovery.  Harden and Young dialyzed yeast extract; thereby 
separating the yeast extract into a dialysate and a residue.  They found that the dialysate 
contained a substance that promoted fermentation, even when the dialysate was boiled 
(37).  In a subsequent paper, Harden and Young described the component of the yeast 
extract as a “coferment” (aka coenzyme), and showed that the coferment did not restore 
fermentation to the inactivated residue of the yeast extract (38).    
 
Enzyme Kinetics 
At this time, the definition of a catalyst was ambiguous.  Wilhelm Ostwald, a 
professor of Chemistry at Leipzig University, spent much of his time devoted to 
understanding catalysis, chemical equilibrium and rates of reaction.  In addition to 
teaching a number of future high profile scientists, including Svante Arrhenius, Jacobus 
H. van‟t Hoff, and Walther Nernst, he correctly defined a catalyst as a component that 
increased the velocity of a chemical reaction while remaining unchanged itself (39).  In 
addition, the catalyst must increase the velocity of a reversible reaction in both forward 
and reverse directions.  Berzelius may have coined the term “catalyst”, but it is 
Ostwald‟s definition of catalysis that we use today.   
Another contribution to the notion that enzymes behaved like catalysts came 
from Arthur Croft Hill (35).  In 1898, while studying the hydrolysis of maltose into two 
molecules of glucose by maltase, he found that exposing maltase to high concentrations 
of glucose caused the production of a significant amount of maltose (40).  At the time of 
A. C. Hill‟s experiments, hydrolysis was known to be a reversible reaction.  Hill‟s 
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experiments showed that maltase catalyzed the reverse reaction thus helping to further 
the concept that enzymes are catalysts and that enzymes are capable of various types of 
reactions, including synthesis. 
 The concept that enzymes act as catalysts initiated the desire to understand how 
the enzyme action worked.  From this desire sprung the beginnings of enzyme kinetics 
which can be traced to a paper written in 1890 by Cornelius O‟Sullivan and Frederick 
W. Tompson.  They reported the results of an extensive study of invertase that examined 
the consequences of numerous variables such as quantity of enzyme and substrate, 
temperature, acidity, and alkalinity on the rate of inversion.  They concluded that the 
enzyme followed the law of mass action, and the few instances when it did not were due 
to the differences in experimental conditions (41).  This conclusion was important, 
although highly disputed, because for the first time the actions of an enzyme were being 
compared to a chemical reaction that takes place without a living organism.  In other 
words, if the chemical laws were the same for the living and non-living worlds, then the 
validity of enzymes containing a „vital force‟ was called into question.  In addition, they 
showed that invertase combined with sucrose could withstand a temperature 25° higher 
than invertase alone.  They explained this result by stating, “We are of [the] opinion that 
when invertase hydrolyses cane-sugar, combination takes place between the two 
substances, and the invertase remains in combination with the invert-sugar.” (41).  This 
is probably the first mention of the enzyme forming a complex with the substrate. 
 Just four years after O‟Sullivan and Tompson published their paper, Emil Fischer 
proposed what may have been the first theory of enzyme action, which is extraordinary 
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given the fact that the fundamental nature of enzymes was still unknown.  Fischer was 
initially interested in the stereochemistry of sugars, an interest that eventually evolved 
into a quest to understand the fermentability of different sugars.  Fischer and his 
colleague H. Thierfelder obtained twelve different species of yeast and looked at how 
each species reacted with different sugars (42).  He found that the yeast‟s behavior 
varied greatly depending on the sugar, and hypothesized that the yeast cells possess 
chemical agents with a configuration that allows them to react with sugars of a similar 
configuration (6, 43).  To test this hypothesis, Fischer proceeded to conduct experiments 
where he showed that invertase reacted with the α-glucoside but not the β-glucoside, and 
that emulsin reacted with the β-glucoside but not the α-glucoside (43).  Fischer 
discovered that enzymes were selective in the substrate they bound.  He explained this 
selectivity of enzymes  with the following statement,  “To use a metaphor, I would say 
that enzyme and glucoside must fit together like lock and key in order to exert a 
chemical effect on each other.” (20, 43).   
In 1904, a student of Fischer‟s, Edward F. Armstrong,  provided proof in support 
of Fischer‟s findings that the enzyme forms a complex with the substrate (44, 45).  
Armstrong did experiments similar to Fischer‟s invertase/emulsin glucoside experiments 
where he measured the rate of hydrolysis of four hexases after the addition of different 
hexoses and hexosides.  He found that the only hexoses that inhibited the corresponding 
enzyme are those that are derived from the same (45).  He also showed evidence of 
product inhibition which was more proof that enzymes underwent reversible reactions 
(45).   
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O‟Sullivan and Tompson‟s 1890 paper provided evidence that the enzyme reacts 
with sucrose much the same way that acid reacts with sucrose and invertase follows the 
law of mass action (41).  This observation was met with opposition from Adrian Brown, 
Victor Henri, and Emil Duclaux.  Brown expressed concern with how O‟Sullivan and 
Tompson prepared their invertase, stating that the amount of acid they used for 
purification “varied in every experiment in a most remarkable manner” (46).  Brown 
believed that the enzyme O‟Sullivan and Tompson used was compromised.  Also, 
Brown and Duclaux criticized O‟Sullivan and Tompson for basing their conclusion on a 
logarithmic curve that represented the activity of invertase.  O‟Sullivan and Tompson 
reported, based on this curve, that invertase compared quite nicely to a logarithmic curve 
representing mass action (41).  O‟Sullivan and Tompson used the following equation: 
v = 1 t log
1
1-
 P 
 S °
 
    (1-1) 
where v is the rate or velocity of the reaction, t is the time, [P] is the concentration of the 
enzyme, and [S]o is the initial substrate concentration.  The above equation follows the 
law of mass action if the velocity of the reaction remains constant.  However, Henri and 
Brown independently reported that the velocity of invertase was not constant, but 
steadily increased (46, 47).  Duclaux reported that there was a difference between the 
action of acids and the action of invertase (48).  The work of Henri, Brown, and Duclaux 
clearly showed that invertase did not follow mass action. 
 Brown showed in his paper, aptly titled “Enzyme Action,” that the rate of 
invertase depended on a time factor that accompanied molecular combination.  Brown 
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theorized that an enzyme-substrate complex must exist before the substrate was changed.  
Also, Brown described in detail product inhibition and introduced the concept that 
enzymes had a maximal rate of reaction, or maximal velocity (Vmax) (46).  
Unfortunately, Brown used the generic rate equation (Equation 1-1) used by O‟Sullivan 
and Tompson to describe the actions of invertase, which posed numerous problems.  
Brown was criticized for assuming that the enzyme-substrate complex had a fixed 
lifetime and for using an equation to describe a rate that did not take into account the 
changing substrate concentration (49).  In addition, Brown‟s equation did not factor in 
the affinity of the enzyme for the substrate or the Vmax.  Henri wrote a paper in 1902, the 
same year as Brown‟s paper and like Brown, proposed a transient enzyme-substrate; 
however, unlike Brown, Henri‟s rate equation included terms for both the substrate 
concentration ([S]) and Vmax, shown here in Equation 1-2 (47): 
v = 
Vmax S 
1+m S +n P 
     (1-2) 
where m and n represent independent variables and [P] represents the enzyme 
concentration. 
Søren P. L. Sørensen was interested in determining methods that would measure 
hydrogen ion concentrations.  In 1909, he wrote a substantial paper which introduced the 
importance of hydrogen ion concentration and emphasized the impact this had on 
enzyme processes.  He invented the concept of pH and demonstrated the importance pH 
had on enzyme activity.  His experiments effectively proved that pH was a factor that 
was just as important as temperature to enzyme activity (6, 50).   
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 Henri‟s equation (Equation 1-2] and Sørensen‟s findings were used by Leonor 
Michaelis and Maud Menten to derive their enzymatic rate equation, often referred to as 
the Michaelis-Menten-Henri equation (M-M equation).  This was the first equation that 
included terms for the substrate concentration ([S]), Vmax, and substrate affinity (Km), 
shown below in Equation 1-3 (51): 
v = 
Vmax S 
 S +Km
     (1-3) 
The introduction of this rate equation often overshadows the other very significant 
observations Michaelis and Menten made in their 1913 paper.  They conducted 
experiments where a pH optimum for invertase was determined and were the first to 
propose the usage of buffers for enzyme storage and assays.  Michaelis and Menton also 
showed that they could prevent complications that arose from product inhibition by 
measuring the initial enzymatic rate upon substrate addition (51). 
 Michaelis-Menten kinetics represents the simplest case of enzyme kinetics, or 
single-substrate kinetics, shown here: 
E + S           ES           E + P 
where E, S, and P represent the enzyme, substrate, and product, respectively, and k 
represents the rate constants.  Michaelis and Menten assumed the rapid equilibrium 
approximation where k3 is much smaller than k2 in deriving their substrate affinity 
constant (Km).  This meant that the Km is approximately the same as the dissociation 
constant for the substrate (Kd) where Kd equals k2/k1.  In 1914, a year after Michaelis 
and Menten published their paper, Donald D. Van Slyke and his assistant, G. E. Cullen, 
independently developed an equation that was very similar to that of Michaelis and 
k1 
k2 
k3 
18 
 
 
Menten (52).  Van Slyke and Cullen were working with urease, whereas Michaelis and 
Menten were working with invertase; therefore, the assumptions that Van Slyke and 
Cullen made about the kinetics of urease were different from invertase.  Van Slyke-
Cullen kinetics is the opposite extreme of Michaelis-Menten kinetics in that k3 is much 
greater than k2.  George E. Briggs and John B. S. Haldane proposed a more general 
version of the Michaelis-Menten equation in 1925 where k1, k2, and k3 are all 
comparable to each other; therefore, the Km would equal (k3+k2)/k1 (53) which is also 
called the quasi-steady state approximation.  Interestingly, biochemistry textbooks today 
introduce the Michaelis-Menten-Briggs-Haldane version of the Michaelis-Menten 
equation, even though it is not what Michaelis and Menten originally intended. 
 
Hemoglobin 
While Henri, Brown, Michaelis, Menten, and others were busy defining an 
equation which described enzyme action, Archibald V. Hill was deriving an equation 
that described the binding actions of a known protein, hemoglobin.  In 1910 Archibald 
Vivian Hill published a short paper titled “The possible effects of the aggregation of the 
molecules of hemoglobin on its dissociation curves” (54).  Hill noticed that experimental 
results for the oxygen saturation curve of hemoglobin varied greatly depending on the 
preparation of the protein.  At the time, researchers knew that hemoglobin was a 
multimer; but did not know the oligomeric state of the protein.  Hill wanted to derive an 
equation that would describe hemoglobin‟s response to oxygen, no matter the oligomeric 
state of the protein.  He proposed three equations that accurately described the binding of 
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oxygen to hemoglobin.  The equation that became known as the Hill equation was his 
equation B, or Equation 1-4 shown here: 
y = 100
Kxn
1+Kxn
     (1-4) 
where y is the percentage of hemoglobin saturation with oxygen, x is the partial pressure 
of oxygen, K is the equilibrium constant, and n represents the number of molecules of 
hemoglobin (54).  This equation is easily adapted to fit experimental data from 
numerous reactions (55).  One adaptation is the Michaelis-Menton equation (Equation 1-
3), which is essentially a modified example of the Hill equation. 
 Hemoglobin is an important protein, especially in the realm of allostery, since it 
is the quintessential allosteric protein in the literature.  Hemoglobin has been studied for 
nearly two centuries because of the high availability of the protein (the concentration of 
hemoglobin in blood is about 25 mM) and hemoglobin‟s binding to oxygen is easily 
detected with spectrophotometric techniques.  In 1747, Vinvenzo Menghini was the first 
to show that blood contained significant amounts of iron by burning the blood and 
showing that the ashes were magnetic (56).  Berzelius separated the erythrocyte into two 
components: a protein component which he named “globin” and a colored “haem” 
component which contained the iron oxide (57).  In 1862, Felix Hoppe-Seyler named the 
red pigment of blood “hemoglobin” and was able to crystallize and describe the 
spectrum of the protein (58).  Hoppe-Seyler also showed that oxygen formed a bond 
with hemoglobin, which he named oxyhemoglobin (58).  Paul Bert, in 1878, was the 
first to discover the relationship between pressure and the amount of oxygen when he 
exposed animals to different barometric pressures and measured the amount of oxygen 
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in the animal‟s blood (59).  In 1903, Christian Bohr described the sigmoidal response of 
hemoglobin to oxygen and reported the first occurrence of homotropic cooperativity in 
the literature (60).  Homotropic cooperativity described the binding of hemoglobin to 
oxygen such that hemoglobin‟s affinity for oxygen increased as more oxygen was added.  
One year later, Bohr, along with Karl Hasselbalch and August Krogh, showed that at 
higher carbon dioxide levels the affinity of the hemoglobin for oxygen decreased, which 
later became known as the “Bohr effect” (61).   This paper was the first to describe 
heterotropic cooperativity, which is the effect carbon dioxide had on hemoglobin‟s 
affinity for oxygen.  In more generic terms, homotropic cooperativity is defined as 
interactions that take place between like ligands and heterotropic cooperativity are 
interactions that take place between different ligands.   
 
Classification of Enzymes as Protein 
The relationship between proteins and enzymes was not known during the first 
couple of decades of the 20
th
 century.  In fact, the nature of the composition of enzymes 
was the subject of another heated debate.  Many scientists hypothesized that enzymes 
were proteins; however, the dominant opinion belonged to Richard Willstätter, a trusted 
and well respected German scientist who did not believe enzymes were proteins.  
Instead, Willstätter developed the “carrier theory” for enzymes where a carrier was 
defined as any colloid, such as a protein or a carbohydrate, which could carry an 
enzyme.  The carrier was able to exchange with other carriers and the composition of the 
enzyme was an unknown chemical compound (62).    In 1926, after nine years of trial 
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and error, James Sumner demonstrated that he could purify and crystallize urease and 
that these crystals were “purely protein in so far as can be determined by chemical tests” 
(63).   Sumner‟s results were immediately dismissed by Willstätter and his followers.  
However, four years later John H. Northrop published a paper in which he described the 
crystallization of pepsin, a well characterized enzyme (64).  Northrop ran numerous 
assays on the crystallized pepsin, including solubility, temperature, and rate of diffusion 
assays.  He concluded that pepsin was indeed a protein, supporting Sumner‟s work.  
After numerous other reports of enzymes being proteins (a review of these papers in 
(62)), it was finally excepted that enzymes were indeed composed of proteins.     
 In 1958 there was an explosion of discoveries in the area of proteins and 
enzymes.  Francis Crick gave a speech in 1958 at the Symposium of the Society for 
Experimental Biology titled “On Protein Synthesis” where he introduced the central 
dogma of molecular biology, which explained how proteins are synthesized in cells (65).  
During the same year, Daniel E. Koshland introduced  the induced fit model for enzyme 
catalysis which updated Emil Fischer‟s lock and key model (66).  The lock and key 
model assumed a rigid enzyme whereas Koshland‟s induced fit model assumed a 
flexible enzyme which allowed the substrate to determine the enzyme‟s final shape.  
Max Perutz introduced a novel technique in 1953 which solved a long standing problem 
in protein crystallography in which he demonstrated that isomorphous replacement of 
heavy atoms in a protein allowed for the protein‟s structure to be solved (67).  This 
method came to fruition in 1958 when John C. Kendrew and associates published the 
first ever crystal structure of a macromolecule, which was myoglobin (68).  Just one year 
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later, in 1959, Perutz solved the crystal structure for hemoglobin bound to oxygen 
(69)(for an in depth review of Perutz‟s discoveries see (70)), which is the first crystal 
structure of an allosteric protein. 
 
Enzyme Regulation 
The 1950‟s also saw the recognition of three forms of enzyme regulation.  One 
form of enzyme regulation considers the amount of enzyme present inside the cell that is 
control of gene expression.  This form of enzyme regulation was first discovered by 
Jacques Monod, Germaine Cohen-Bazire, and Melvin Cohn in 1951 (71, 72).  Monod 
and his associates measured the amount of β-galactosidase produced by Escherichia coli 
(E. coli) in response to several different β-galactosides.  They found that the β-
galactosides that acted as inducers of the enzyme did not resemble the substrate, lactose.  
They discovered the inducers of β-galactosidase were activating gene expression for the 
enzyme and not directly binding to the enzyme.  In 1957, two independent groups of 
investigators found that genetic control of the production of enzymes can be controlled 
through gene repression by end-product metabolites.  Luigi Gorini and Werner Mass 
showed that the cellular concentration of arginine or derivatives of arginine in E. coli 
controlled the rate of formation of ornithine transcarbamylase (73).  Richard A. Yates 
and Arthur B. Pardee used inhibition studies and radioactive metabolite assays to 
determine that three enzymes involved in the making of orotic acid in E. coli are 
controlled by a mechanism of enzyme repression at the genetic level (74).   
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 The second type of enzyme regulation elucidated in the 1950‟s is covalent 
modification of the enzyme itself by a small molecule, such as a phosphate group.  
George Burnett and Eugene P. Kennedy described in their 1954 paper an enzyme in rat 
mitochondria that is capable of catalyzing the phosphorylation of a protein substrate by 
MgATP (75).  This first description of a protein kinase was soon followed by the 
discovery of regulation of glycogen phosphorylase via phosphorylation in 1955 (76-78).  
In a series of papers, Edwin G. Krebs and Edmond H. Fischer described how the inactive 
form of the enzyme, glycogen phosphorylase b, in resting muscle is converted to the 
active form of the enzyme, phosporylase a, by phosphorylase kinase.   
 A method was developed in 1950 by Bernard D. Davis that made the isolation of 
mutant strains of E. coli practical and easy (79).  Thanks to this method another form of 
enzyme regulation called feedback inhibition was discovered.  Aaron Novick and Leo 
Szilard, using a new instrument they called a chemostat, conducted experiments in 
which they isolated E. coli strains that were deficient in tryptophan synthesis (80).  They 
conducted in-vivo E. coli experiments which showed that the synthesis of indole-3-
glycerol phosphate, a precursor of tryptophan, was rapidly inhibited by the addition of 
typtophan to the media.  Novick and Szilard hypothesized that an enzyme which 
catalyzes a reaction early on in a metabolic pathway can be inhibited by an end product 
of the same pathway.  H. Edwin Umbarger published a very short, but important, paper 
in 1956 in which he went one step further than Novick and Szilard by preparing cell-free 
extracts of E. coli, and showed that the addition of isoleucine inhibited the first 
committed step of the isoleucine metabolic pathway (81).  Later, in a talk given at the 
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26
th
 annual Cold Spring Harbor Symposium on Quantitative Biology in 1961, Jacques 
Monod defined a new name for feedback inhibition when he stated, “From the point of 
view of mechanisms, the most remarkable feature of the Novick-Szilard-Umbarger 
effect is that the inhibitor is not a steric analogue of the substrate.  We propose therefore 
to designate this mechanism as „allosteric inhibition‟.” (82). 
 
Allostery Theory 
After the discovery of feedback inhibition, two groups of researchers have been 
credited with developing the “two-site theory” for allosteric enzymes.  John C. Gerhart, 
a graduate student of Arthur B. Pardee, worked with aspartate transcarbamylase and Jean 
P. Changeux, a graduate student of Monod, worked with threonine deaminase. Gerhart 
and Pardee knew that aspartate transcarbamylase was inhibited by cytidine triphosphate 
(CTP), an end product of the pathway.  They showed that the inhibition by CTP was 
reversed by addition of high concentrations of one of the enzyme substrates and that the 
Vmax of the enzyme remained the same even in the presence of CTP.  Gerhart and Pardee 
altered aspartate transcarbamylase from E. coli by applying heat, urea, and heavy metal 
ion additions so that the enzyme was no longer sensitive to CTP inhibition; however, the 
enzyme still catalyzed its substrates.  The authors of this paper state: 
 It is concluded that the surface of aspartate transcarbamylase contains an 
exclusive site for binding CTP, the feedback inhibitor.  This feedback site 
is distinct from the active site but appears to influence the function of the 
latter (83).   
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Changeux and Monod altered threonine deaminase from E. coli using methods such as 
mutagenesis and chemical treatments to create mutants which were not sensitive to 
inhibition but still active (84).  The discoveries of Gerhart and Changeux were reported 
in 1961; therefore, both of these groups are credited with being the first to define 
allosteric enzymes as enzymes that bind regulating metabolites, also called effectors, at 
distinct binding sites separate from the substrate binding site or active site.  The effector 
then regulates the activity of the enzyme by altering either the enzyme‟s affinity for the 
substrate (K-type) or its catalytic activity (V-type).  Furthermore, the effector is an 
inhibitor if it decreases the protein‟s affinity for its substrate, and it is an activator if it 
increases the protein‟s affinity for its substrate. 
 Four years after Gerhart and Changeux‟s publications reporting the allosteric 
phenomenon, Jacque Monod, Jeffries Wyman, and Jean P. Changeux published their 
model explaining the behavior of allosteric proteins.  They were looking for a simple 
physical interpretation of the allosteric phenomena in terms of structure (85).   Their 
model, also called the concerted model or the MWC model, was based on properties of 
all known allosteric proteins and enzymes available in 1965.  Monod, Wyman, and 
Changeux compared the 24 allosteric proteins and enzymes and noticed that most of 
their saturation functions were not linear, like that of a non-allosteric enzyme would be, 
but were instead sigmoidal.  Years before, in 1950, Wyman  predicted that hemoglobin 
was structurally symmetrical based on its symmetrical oxygen saturation (86).  Wyman‟s 
expectation proved to be correct once Perutz came out with his structure of hemoglobin 
(69).  Following this observation, Monod, Wyman, and Changeux proposed their model 
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which basically states that there is a preexisting equilibrium between two possible forms 
of the enzyme, the T or tense form has a low affinity for the substrate and the R or 
relaxed form has a high affinity for the substrate (87).  According to this model, all 
subunits in the enzyme exist wholly in either the R or T form, so that when the enzyme 
changes from one form to the other, all subunits do so in a concerted or cooperative 
manner.  The MWC model also states that the substrate and the allosteric activator 
stabilize the R form of the enzyme just as the allosteric inhibitor stabilizes the T form of 
the enzyme.   
Soon after the release of the MWC model, Koshland, Némethy, and Filmer 
proposed the KNF or sequential model (88).  The KNF model uses the same notations as 
the MWC model, such as R and T; however, there are a few differences.  The KNF 
model predicts that only the subunit that binds the ligand (either substrate or effector) 
undergoes a conformational change, while the subunits that do not bind the ligand 
remain unchanged.  This allows for negative cooperativity, a condition not allowed for in 
the MWC model.  In other words, the subunit that is bound by the ligand can influence 
the neighboring subunits.  If the bound subunit‟s influence is favorable, then the 
cooperativity that ensues is positive.  If the bound subunit‟s influence is unfavorable, 
then the cooperativity that ensues is negative.  Also, the KNF model does not assume a 
preexisting equilibrium between R and T forms; instead, it predicts that the ligand (either 
substrate or effector) will influence the conformation the enzyme adopts.   
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Allostery and Kinetics 
The discovery of allosteric enzymes initiated research into the kinetics of these 
unique enzymes.  Carl Frieden wrote a paper in 1964 that addressed “the question of 
how to treat the data for enzymes which are influenced by substances binding 
specifically to sites other than the enzymatically active site” (89).  In this paper Frieden 
introduced the single substrate-single modifier case, shown in Figure 1-1.  The single 
substrate-single modifier case represents a simplified scenario in which there is one 
substrate and one product bound by the enzyme, and the enzyme possesses one effector 
site and one substrate site.  There may be more than one effector or substrate site per 
enzyme; however, all similar sites are considered to be independent and identical.  
Frieden derived equations using both the rapid equilibrium and the steady state 
assumptions for enzyme mechanisms in which there is a single substrate site and a single 
effector site (89). 
J. Wyman, in addition to collaborating with Monod and Changeux on the MWC 
model, wrote several papers elucidating the general concept of linkage (90-92).  Wyman 
explained linkage in his 1948 paper with, “Whenever a molecule possesses two or more 
different functions there is the likelihood of an interdependence of these functions due to 
interaction between the groups.” (92).  Wyman believed that through studying the 
linkage between several reactions within a complex molecule one could describe the 
structure and function of the molecule.  Soon after the publication of the MWC model 
was released; Wyman published a paper describing allosteric linkage in which he was 
the first to relate the allosteric nature of a macromolecule to thermodynamics by 
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introducing the allosteric binding potential  (93).  This binding potential quantified the 
allosteric response of a macromolecule.  Wyman used chemical potentials to imply 
reciprocity, which means that the binding of the effector has the same influence on the 
binding of the substrate as the binding of the substrate has on the binding of the effector.    
 
 
 
E   +   A           EA          E   +   P 
   +          +  
   X          X 
 
 
   XE  +  A          XEA         XE  +  P 
 
Figure 1-1  Single substrate-single modifier scheme.  Where E, A, X, and P represent 
enzyme, substrate, effector, and product, respectively, and the various k‟s represent the 
rate constant of the corresponding reaction. 
 
 
 
Gregorio Weber described a new approach to Wyman‟s linkage theory in papers 
written between 1968 and 1975.  Weber defined allosteric linkage as interactions that 
occur within a macromolecule between two ligands which bind at distinct sites.    Weber 
demonstrated that allosteric linkage can be written in thermodynamic terms of free 
energy, in which he introduced the concept of coupling free energy (94, 95).  Gregory D. 
Reinhart simplified Wyman‟s and Weber‟s ideas into more intuitive relationships.  
Reinhart applied the kinetic notations first used by W. Wallace Cleland and the single 
substrate-single modifier scheme created by Frieden (see Figure 1-1) to describe the 
thermodynamic relationships previously defined by Weber (89, 94-98).  The relationship 
between the binding of effector (X) and the binding of substrate (A) was defined as the 
k2 
k1 k3 
k9 
 k12 k11  k6 k5 
k8 
k7 
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coupling free energy which quantifies both the nature and the magnitude of an allosteric 
effect.  The coupling free energy, or ∆Gax, is expressed in terms of standard free energy 
by using the following equation (94, 95): 
                                                         ∆Gax=-RTlnQax                                               (1-5) 
where Q
ax
  is the coupling constant that is equal to the ratio of the following values: 
                                                            Q
ax
=
Kia
°
Kia
∞ =
Kix
°
Kix
∞ .           (1-6) 
Kia
°  and Kia
∞°are the dissociation constants for A in the absence and saturating presence of 
X, respectively, and Kix
°  and  Kix
∞  are the dissociation constants for X in the absence and 
saturating presence of A.  The relationship defined in Equation 1-6 describes the notion 
of reciprocity, first introduced by Wyman in terms of chemical potential. The 
dissociation constants can also be defined, with reference to Figure 1-1, as: 
                                                           Kia
° =
 E  A 
 EA 
=
k2
k1
                                                   (1-7) 
                                                         Kix
° =
 E  X 
 XE 
=
k6
k5
                                                  (1-8) 
                                                        Kia
∞=
 XE  A 
 XEA 
=
k8
k7
                                                 (1-9) 
               Kix
∞=
 EA  X 
 XEA 
=
k12
k11
.                                             (1-10) 
Therefore, if ∆Gax is negative (or Qax > 1), then the allosteric effector is an activator and 
if ∆Gax is positive (or Qax< 1), the allosteric effector is an inhibitor.  When ∆Gax is equal 
to zero (or Q
ax
= 1) there is no allosteric effect.  The above definitions reveal that Q
ax
 is 
the equilibrium constant for the following disproportionation equilibrium: 
       XE + EA 
Qax
 XEA + E.                                        (1-11) 
30 
 
 
In 1987, Reinhart applied Weber‟s thermodynamic approach to derive relationships 
between the Hill number, the concentration of the effector, the coupling free energy, and 
the dissociation constants for a theoretical allosteric homodimer (99).  Through the 
mathematical advancements of Frieden, Wyman, Weber, and Reinhart; we now have an 
effective and descriptive way of describing the allosteric reaction for any enzyme. 
 One of the first enzymes described using the MWC model was 
phosphofructokinase (PFK) from E. coli (100).  Daniel Blangy, H. Buc, and Monod 
published a paper in 1968 detailing the kinetics of the allosteric homotetramer PFK.  
PFK catalyzes the first committed step of glycolysis, transferring a phosphate group 
from MgATP to fructose-6-phosphate (F6P) making MgADP and fructose-1-6-
bisphosphate (F16BP).  Prokaryotic PFK is a highly regulated enzyme that is 
allosterically inhibited by phosphoenolpyruvate (PEP) and allosterically activated by 
MgADP.  Both PEP and MgADP bind to the same effector binding site.  Blangy, Buc, 
and Monod reported data detailing the kinetics, activation, and inhibition of E. coli PFK 
and concluded that the enzyme was “a perfect K system, i.e. one where the kinetic 
parameter Vmax is invariant” (100).  They also wrote in their conclusions that “The 
results reported in the present paper and their analysis may be summarized by saying 
that the kinetic behavior of PFK with respect to its substrate, activators, and inhibitors, is 
quantitatively accounted for by a model based on the concerted transition theory” (100).  
About twenty years later, Tilman Schirmer and Philip R. Evans had crystallized the 
substrate bound form and the phosphoglycolate (PGA), a PEP analog, bound form of 
Bacillus stearothermophilus PFK (BsPFK) (101).  EcPFK and BsPFK share 55% amino 
31 
 
 
acid identity and both are inhibited by PEP and activated by MgADP.  When the crystal 
structures of the substrate-bound and the PGA-bound enzymes are compared there is a 
conformational change that occurs in the PGA-bound BsPFK structure relative to the 
substrate-bound structure.  The conformational change includes a difference in the 
quaternary structures of the two enzyme forms.  The quaternary structure of the 
inhibitor-bound BsPFK has undergone a 7° rotation about the substrate-binding 
interface, termed the quaternary shift, when compared to the substrate-bound BsPFK.  
The conformational change also includes the movement of residues E161 and R162 in 
the active site.  When F6P is bound to the enzyme, the positively charged R group of 
R162 interacts with the negatively charged phosphate group of F6P.  In the PGA bound 
structure, R162 is replaced by the negatively charged R group of E161.  Given the 
structural differences seen between the substrate bound and inhibitor bound structures of 
BsPFK, Schirmer and Evans were confident that they had all the evidence needed to 
prove that the MWC model was accurate in describing the allosteric behavior for 
prokaryotic PFK.  In fact, the structural basis for the allosteric nature of BsPFK has been 
used as an example of allosteric regulation in textbooks (102, 103).   
Reinhart has provided a great deal of evidence that contradicts many previous 
predictions concerning prokaryotic PFK.  For example, Jennifer Kimmel and Reinhart 
measured the thermodynamic parameters of active site mutants of BsPFK.    They 
showed that the switching of E161 and R162 in the active sites of the substrate bound 
and PGA bound structures of BsPFK did not adequately explain the allosteric inhibition 
of the enzyme by PEP (104).  The study by Kimmel and Reinhart is supported by the 
32 
 
 
findings of Braxton, et. al. in which MgADP, a weak activator of BsPFK at moderate 
temperatures, becomes an allosteric inhibitor at temperatures below 16°C (105).  A key 
component of the MWC model is that allosteric activators and inhibitors bind to distinct 
forms of the enzyme.  Accordingly, MgADP would stabilize the active site of BsPFK so 
that F6P can more readily bind to the enzyme.  However, Braxton, et. al. showed that the 
structure alone could not explain how MgADP becomes an inhibitor at lower 
temperatures (105).  Braxton et. al. also pointed out that attributing the allosteric nature 
of BsPFK to structural perturbations alone addressed the enthalpic component of the 
coupling free energy, but ignored the entropic component completely [4].  Tlapak-
Simmons and Reinhart addressed the differences in the kinetics and allosteric properties 
of BsPFK with PEP, the native allosteric inhibitor of BsPFK, and PGA, the PEP analog 
that is present in the inhibited form of BsPFK (106).  Schirmer and Evans reasoned that 
the PGA structure would exhibit the same structural characteristics as the PEP structure 
since the two components are structurally similar (101).  Tlapak-Simmons and Reinhart 
showed that while PEP and PGA are both K-type inhibitors of BsPFK, they differ 
significantly in both their binding affinity and coupling. (106).  The aforementioned 
studies provide evidence that does not support the model asserted by Schirmer and 
Evans. 
 Other groups have also found contradictions to the MWC and KNF models.  In 
1984, A. Cooper and D.T.F. Dryden proposed a model for dynamic allostery, in which 
allosteric regulation occurs without the advent of a conformational change (107).  R. 
Ranganathan and S.W. Lockless proposed a new approach in which one could identify 
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allosteric networks within a protein (108).  Monomeric and single domain proteins have 
been shown to be allosteric (109, 110).  Also, in 2006, Popovych, et. al. reported 
negative allostery in an enzyme that did not undergo a conformational change (111).    
The view of allostery has been expanded far beyond the restricted confines of the 
concerted and sequential models.  In a recent review, Ruth Nussinov summed up the 
new view of allostery with (112): 
1)   Allosteric proteins exist in numerous conformations  
2) Allostery is thermodynamic phenomenon which can exist as being    
enthalpically, enthalpically and entropically, or just entropically dominated.   
3)   Allosteric proteins have multiple conformational and dynamic states meaning 
that there will be multiple pathways for which the allosteric communication will 
be relayed.   
All in all, it appears that the field of allosteric proteins is still expanding, with new 
discoveries and ideas being added to the annals of history every day.  Maybe Monod had 
it right almost 50 years ago when he said “In any case, one may predict that “allosteric 
enzymes” will become a favorite object of research, in the hands of students of the 
mechanisms of enzyme action” (82).  
 
The Present Study 
 The allosteric regulation of BsPFK has been extensively studied throughout the 
years and been the topic of many interesting journal articles.  Many facets of the 
enzyme‟s characteristics have been elucidated; however, as demonstrated throughout 
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chapter I, with every question answered, there follows countless more questions.  Such is 
the case for BsPFK.  The current investigation attempts to address a few queries 
concerning the structure and function relationship of BsPFK. 
 Chapter II deals with the apo BsPFK crystal structure and its importance to the 
understanding of the allosteric nature of the enzyme.  Chapter III concentrates on the 
function of the quaternary shift in BsPFK.  The variants D12A BsPFK and T156A 
BsPFK were crystallized and illustrate the enzyme to be in the quaternary shifted 
position similar to the PGA-bound structure of wild-type BsPFK.  Kinetic 
characterization of both variants demonstrates that the single mutations significantly 
alter the enzyme‟s ligand affinities without significantly changing their coupling values.  
Chapter III also focuses on the roles of D12 and T156 in ligand binding and coupling for 
BsPFK.  The use of methyl TROSY NMR spectroscopy is introduced in Chapter IV as a 
tool to delve into the structure of BsPFK bound to both inhibitor and substrate 
simultaneously.  In addition, methyl TROSY NMR spectroscopy is attempted with the 
variant D12A BsPFK in order to obtain additional structural information.  Finally, 
Chapter V summarizes the results discussed throughout the dissertation and alludes to 
possible future work.   
The following dissertation is a humble contribution to the annals of history 
concerning the regulation of allosteric enzymes.  Hopefully, it will provide some clarity 
for future generations interested in asking questions about BsPFK. 
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CHAPTER II 
STRUCTURE OF THE APO FORM OF BACILLUS STEAROTHERMOPHILUS 
PHOSPHOFRUCTOKINASE 
 
Phosphofructokinase (PFK) is under strong metabolic regulation because it 
catalyzes the first committed step of glycolysis in which it transfers the γ-phosphate 
from MgATP to fructose-6-phosphate (F6P) making MgADP and fructose-1, 6-
bisphosphate (F1,6BP).  Not surprisingly, PFK is the subject of intense study and often 
serves as a key example of an allosteric enzyme (102, 103).  Eukaryotic PFKs have very 
complex regulation involving many effectors (113) and, to date, none of those structures 
have been solved.  Insight into the allosteric regulation of eukaryotic PFKs can be 
gleaned through the study of the much simpler regulation exhibited by prokaryotic 
PFKs.  The two most thoroughly characterized prokaryotic PFKs are from Escherichia 
coli (Ec) and Bacillus stearothermophilus (Bs) (100, 114).  EcPFK and BsPFK share 
55% amino acid identity and both are homotetramers with a molecular weight of 34 KDa 
per monomer (115).  Both enzymes are regulated by the K-type effectors 
phospho(enol)pyruvate (PEP), an allosteric inhibitor, and MgADP, an allosteric 
activator.  Furthermore, PEP and MgADP bind to the same allosteric site.  EcPFK and 
BsPFK have two unique dimer-dimer interfaces, the substrate-binding interface and the 
effector-binding interface.  The substrate-binding interface contains the F6P binding site, 
which is comprised of amino-acids from two adjacent monomers.  Likewise, the 
effector-binding interface possesses the allosteric ligand binding site which is made up 
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of amino acids from two adjacent monomers.  Each homotetramer possesses four 
identical F6P binding sites and four identical effector binding sites. 
Currently, there are seven crystal structures of bacterial ATP-dependent PFKs in 
the Protein Data Bank (PDB).  Of the seven structures, only one does not originate from 
EcPFK or BsPFK.  Lactobacillus delbrueckii PFK (LbPFK) contains 56% and 47% 
amino acid sequence identity to BsPFK and EcPFK, respectively (116).  Despite the high 
sequence identity LbPFK shares with EcPFK and BsPFK, LbPFK exhibits a severely 
diminished capacity to bind both PEP and MgADP (117).  The structure of LbPFK with 
SO4 bound to all four active sites and all four effector sites (accession code 1ZXX) was 
solved by Paricharttanakul, et. al. (117).  The crystal structures of EcPFK include the 
apo enzyme, which was grown in the absence of ligands (accession code 2PFK) (118), 
and the enzyme bound to its reaction products (accession code 1PFK) (119).  The latter 
structure contains the bound reaction products F1,6BP and MgADP in all four active 
sites, and MgADP is bound to all four effector binding sites.  Comparison of the two 
EcPFK crystal structures to each other reveals that their secondary, tertiary, and 
quaternary structures are nearly identical. 
Each of the three crystal structures of BsPFK contains different combinations of 
bound ligands.  Evans, et. al. crystallized BsPFK in a solution containing F6P and then 
proceeded to wash the crystal with a phosphate solution.  The phosphate solution 
reportedly displaced any F6P bound, and allowed for the structure of the phosphate 
bound BsPFK (accession code 3PFK) (120) to be determined.  The phosphate bound 
form of BsPFK contains a phosphate molecule at each of the F6P and effector binding 
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sites for a total of eight bound phosphates.  The crystal structure of BsPFK bound to F6P 
and MgADP in all substrate binding sites and MgADP in all of the effector binding sites 
(accession code 4PFK)(121)  was determined by Evans et. al. and will be referred to as 
the “substrate-bound” BsPFK in the following discussion.  BsPFK was also crystallized 
in the presence of phosphoglycolate (PGA), an analog of the inhibitor PEP, and the 
structure reveals that PGA is bound to all four effector binding sites (accession code 
6PFK)(101).   In a study comparing the binding affinities and allosteric properties of 
BsPFK with PGA and PEP, it was found that PGA inhibits BsPFK in a manner similar, 
though not identical, to PEP (106).  The structures of the phosphate bound and the 
substrate-bound enzymes are very similar to each other; however, the PGA-bound 
BsPFK displays a different conformation.  The crystal structure of BsPFK containing the 
modifications W179F, Y164W revealed that F6P and MgADP were bound in all 
substrate binding sites and MgADP occupied all four effector binding sites (accession 
code 1MTO)(122).  This structure was also found to resemble the substrate-bound form 
of BsPFK.  This variant of BsPFK apparently dissociates in the presence of PEP (122).    
Before any crystal structures of PFK were solved, the allosteric behavior of 
EcPFK was described using the concerted transition model proposed by Monod, 
Wyman, and Changeux (MWC) (87, 100).  Upon solving the structures of the substrate-
bound and the PGA-bound forms of BsPFK, Schirmer and Evans also interpreted the 
differences in these structures in terms of the MWC model (101).  The enzyme was 
described as existing in two states, the substrate-bound form or, R-state, and the PGA-
bound form or, T-state.  Comparison of the substrate-bound and PGA-bound structures 
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of BsPFK reveals that the PGA-bound form has undergone a 7° rotation about the 
substrate binding interface, termed the quaternary shift.  The quaternary shift is 
accompanied by secondary and tertiary changes that include the unwinding of the end of 
helix 6 and the switching of Arg 162 for Glu 161 in the F6P binding site.  Evans, et. al. 
did not obtain an apo BsPFK structure, but concluded that the structure must assume the 
T-state conformation because crystals cracked when substrate was removed (120, 121).   
This prediction was a direct result of assuming the enzyme exists in only two-states. 
In this paper we present the crystal structure of the apo form of wild-type BsPFK, 
determined to 2.8 Å resolution.  This crystal structure serves as a basis for comparison 
for any structural changes seen in the binary or ternary complexes.  In addition, the 
tertiary and quaternary structures of apo BsPFK are different from those originally 
predicted by Evans, et. al. (120, 121).  Contrary to prior expectations, the apo form of 
BsPFK resembles the substrate-bound form of the enzyme, and not the PGA-bound 
form.  The structure of the apo form of BsPFK is therefore an important addition to the 
structural library of allosterically relevant enzyme forms that will help us better 
understand the structural basis of the allosteric mechanism. 
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Materials and Methods 
Materials 
All chemical reagents used in buffers, protein purifications, and enzymatic assays 
were of analytical grade, purchased from Sigma-Aldrich (St. Louis, MO) or Fisher 
Scientific (Fair Lawn, NJ).  Creatine kinase and the ammonium sulfate suspension of 
glycerol-3-phosphate dehydrogenase were purchased from Roche (Indianapolis, IN).  
The ammonium sulfate suspensions of aldolase and triosephosphate isomerase, and the 
sodium salts of phosphocreatine, ATP, and phospho(enol)pyruvate were purchased from 
Sigma-Aldrich.   The coupling enzymes, obtained as ammonium sulfate suspensions, 
were extensively dialyzed against 50 mM MOPS-KOH, pH 7.0, 100 mM KCl, 5 mM 
MgCl2, and 0.1 mM EDTA before use.  The sodium salt of F6P was purchased from 
Sigma-Aldrich or USB Corporation (Cleveland, OH).  NADH and DTT were purchased 
from Research Products International (Mt. Prospect, IL) and the crystallization reagents 
were purchased from Hampton Research (Aliso Viejo, CA).  Mimetic Blue 1 resin used 
for protein purification was purchased from Prometic Biosciences (Rockville, MD).  
Deionized distilled water was used throughout. 
 
Protein Purification 
The plasmid pBR322/BsPFK (123) contains the gene for BsPFK behind the 
native Bacillus stearothermophilus promoter and was received as a generous gift from 
Simon H. Chang (Louisiana State University).  Wild-type BsPFK was expressed in 
E.coli RL257 cells (124), which is a strain of E.coli lacking both the pfkA and pfkB 
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genes.  The purification of BsPFK was performed as described previously, with a few 
modifications (125).  RL257 cells containing the plasmid pBR322/BsPFK were grown at 
37°C for 16-18 hours in LB (Lysogeny Broth) ampicillin (Tryptone 10 g/L, yeast extract 
5 g/L, and Sodium Chloride 10 g/L, ampicillin 100 ug/ml).  Cells were centrifuged and 
frozen at -20°C for at least 12 hours.  The cells were resuspended in purification buffer 
(10 mM Tris-HCl, 1 mM EDTA pH 8.0) and sonicated in a Fisher 550 Sonic 
Dismembrator at 0°C in 15 second pulses at setting 6 for 8 minutes.  The crude lysate 
was centrifuged using a Beckman model J2-21 centrifuge at 22,500 x g for an hour at 
4°C.  The clear supernatant was heated at 70°C for 15 minutes, cooled on ice for 15 
minutes, and centrifuged for one hour at 4°C.  The supernatant was diluted 4-fold and 
then loaded onto a Mimetic Blue 1 column that was equilibrated with purification buffer.  
The column was washed with at least 5 bed volumes of purification buffer, and the 
enzyme was eluted with a 0 – 1 M NaCl gradient.  Fractions containing enzyme were 
pooled and dialyzed into 20 mM Tris-HCl pH 8.5 and loaded onto a Pharmacia Mono-Q 
anion exchange column.  The enzyme was eluted with a 0 to 1 M NaCl gradient, and 
fractions containing PFK were combined, concentrated, then dialyzed into EPPS Buffer 
(50 mM EPPS, 10 mM MgCl2, 100 mM KCl, 0.1 mM EDTA pH 8.0).  Concentrated 
enzyme was stored in EPPS buffer at 4°C.  The final enzyme was determined to be pure 
by SDS-PAGE, and the concentration was ascertained using the absorbance at 280 nm (ε 
= 18910 M
-1
cm
-1
(126)). 
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Crystallization and Data Collection 
BsPFK was crystallized using the hanging drop vapor diffusion method (127) at 
16°C.  Crystallization was achieved in a 4 μl drop consisting of 1 μl of solvent (0.2 M 
calcium acetate hydrate, 0.1 M sodium cacodylate trihydrate pH 6.5, and 18% w/v 
polyethylene glycol 8,000) and 3 μl of protein (stock concentration of BsPFK was 28 
mg/mL).  Within 24 hours, plate BsPFK crystals were formed.  The crystals were briefly 
soaked in 30% ethylene glycol and then flash-frozen in a liquid N2 stream at 100 K.  
Diffraction data were collected on the APS beam line 23-ID (insertion device) using a 
MAR 300 CCD detector (MarMosaic from Marresearch- Charged Coupled Device) 
(Rayonix LLC, Evanston, IL).  The HKL2000 program package (HKL Research, Inc., 
Charlottesville, VA) (128) was used for integration and scaling. 
 
Structure Determination and Refinement 
The molecular replacement program PHASER (University of Cambridge, UK) 
(129) was used to solve the structure of apo BsPFK using the phosphate-bound crystal 
structure of BsPFK (3PFK) (121) with waters and ions removed as a model.  Rigid body 
refinement followed by simulated annealing refinement at 5000 K was carried out using 
Phenix (Python-based Hierarchical Environment for Integrated Xtallography, Berkeley, 
CA) (130).  Subsequently, refinement was carried out in alternating cycles of manual 
model building in COOT (Crystallographic Object-Orientated Toolkit, Oxford, UK) 
(131) followed by refinement in Phenix until the R-factors converged.  The 
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steareochemical quality of the final model of the apo BsPFK enzyme was verified by 
MolProbity (Duke University, Durham, NC) (132). 
 
Results  
Apo BsPFK crystals belong to the space group C2 with unit cell parameters of a 
=201.909 Å, b =113.383 Å, c =76.627 Å and α=90.00°, β=104.030°, γ=90.00°.  Figure 
2-1 shows the asymmetric unit that consists of four monomers or a single tetramer with 
an estimated solvent content of 58.5%.  The final structure was refined to R-factor/R-
free values of 19.9%/26.01% and has a 2.8 Å resolution.  The entire structure consists of 
1,276 residues (319 residues per monomer), 326 water molecules, and five calcium ions.  
The details of the final refinement parameter are shown in Table 2-1. 
The five calcium ions are most likely a crystallization artifact since calcium is a 
main component of the crystallization solution.  Figure 2-1 shows the calcium ions and 
how they appear to bind to the enzyme randomly.  Four of the ions associate with 
aspartate residues and the fifth ion associates with two water molecules and possibly a 
backbone carbonyl group.  Asp 155 from subunits A, B, and C are associated with three 
of the calcium ions and Asp 307 from subunit D is associated with the fourth ion.  
Neither Asp 155 nor Asp 307 is involved in the direct binding of any ligand, and the ions 
are asymmetrically located in the structure.  Apart from the non-specifically bound 
calcium ions, there are no other ligands bound to the enzyme.   
 
 
43 
 
 
Table 2-1  Data collection and refinement statistics
a
  
Data set Apo-BsPFK 
Unit cell (Å)  a = 201.909  
 b = 113.383  
 c = 76.627  
 β= 104.030 
Space group  C2  
Number of molecules per asymmetric unit (Z)  4 monomers 
Resolution  (Å)   50-2.8 
Completeness (%)  98.8(99.2) 
I/ I  14.61(2.80) 
Rsym  11.5 (46.0) 
Refinement 
Resolution  (Å)  50-2.8 
Reflections (working/free)  38382 (1933) 
Rcryst (%)  19.90 
Rfree (%)  26.01 
Number of protein atoms/number of waters  9384/326 
Average B factor (Å2)  42.91 
Average B factor for water molecules (Å2)  44.83 
rmsd bond length (Å)  0.004 
rmsd bond angles (deg)  0.620 
Ramachandran statistics  
     most favored  95.82% 
     allowed  3.63% 
a
 For details of the crystallization and structure determination, see text.  Values in 
parentheses are for high resolution shells.  Rsym = h i|Ihi - Ih |/ h iIhi, where Ihi is 
the ith observation of the reflection h, whereas <Ih> is the means intensity of reflection 
h. Rcryst = |Fo| - |Fc|/|Fo|.  Rfree was calculated with a fraction (5%) of randomly selected 
reflections excluded from refinement.  rmsd, root-mean-square deviations from ideal 
geometry. 
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A. B  
 
Figure 2-1  Apo BsPFK tetramer.  Subunit A colored blue, subunit B colored green, 
subunit C colored yellow, subunit D colored red, and calcium ions colored black. (A) 
View of apo BsPFK showing the substrate binding interface between red and blue 
monomers and green and yellow monomers, allosteric interface between red and yellow 
monomers and blue and green monomers. (B) Alternate view, rotated 90° along the 
horizontal axis. 
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The root-mean-square deviation (RMSD) between apo BsPFK and the substrate-
bound BsPFK is 0.53±0.05 Å for 319 Cα atoms.  The RMSD between apo BsPFK and 
the PGA-bound BsPFK is 0.94±0.05 Å for 319 Cα atoms.  Furthermore, comparison of 
the quaternary structures of the apo, substrate-bound, and PGA-bound forms of the 
enzyme reveals that the apo BsPFK structure has not undergone the quaternary shift seen 
in the PGA-bound structure (Figure 2-2).  Given the values for the RMSDs and the state 
of the quaternary structures, it appears that the apo enzyme is more like the substrate-
bound form than the PGA-bound form.  By contrast, Evans, et. al. (120, 121) observed 
that when crystals formed in the presence of F6P were transferred to a solution lacking 
any activating ligands, the crystals cracked.  Also, crystals grown in the presence of 
inhibitor cracked when exposed to F6P.  The cracking of the crystals was interpreted as 
being an indicator of the enzyme undergoing a large conformational shift, presumable 
the quaternary shift.  However, it is clear that the enzyme has not undergone the 
quaternary shift when crystallized only in the presence of the crystallization solvent.  
One should note, however, that there are also many local differences observed between 
the apo, substrate-bound, and PGA-bound structures.  
The B-factor, or temperature factor, in protein crystal structures is an indicator of 
the fluctuation of an atom about its mean position.  By looking at the distribution of the 
B-factors for an entire protein sequence, information can be derived about the protein‟s 
flexibility and mobility.  Large B-factors reflect areas of higher mobility within the 
crystal structure.  Figure 2-3 is a backbone ribbon structural comparison of the 
crystallographic B-factors for the different wild-type BsPFK crystal structures.  The 
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allosteric interface is seen in Figure 2-3 along the back side of all 3 of the monomers as 
depicted.  The allosteric interface is less flexible than the rest of the monomer for all 
three wild-type crystal structures. The PGA-bound structure shows more rigidity along 
the allosteric interface than the other two wild-type crystal structures, which is indicated 
by the color blue for the lower B-factors (Figure 2-3C).  Clearly the substrate-bound  
 
 
 
 
A.                 B.      C.  
 
Figure 2-2  Comparison of wild-type BsPFK crystal structures. (A) Apo BsPFK (B) 
Substrate-bound BsPFK (accession code 4PFK) (C) PGA-bound BsPFK (accession code 
6PFK). The blue monomer was aligned to the blue monomer of the apo structure for 
each ligand bound structure.  Ligands and heteroatoms have been removed for clarity.  
Each monomer is colored blue, green, yellow, and red.  The substrate binding interfaces 
are between the red and blue monomers and the green and yellow monomers.  The 
effector binding interfaces are between the green and blue monomers and the red and 
yellow monomers.  Areas where there are differences in the tertiary and quaternary 
structures are pointed out with black arrows. 
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A.  
B.                                      C.  
Figure 2-3  Comparison of wild-type BsPFK B-factors.  (A)  Apo BsPFK  (B) Substrate-
bound BsPFK (accession code 4PFK)  (C) PGA-bound BsPFK (accession code 6PFK).   
Only monomer A is shown for each structure.  Bound ligands are depicted as space filled 
molecules, with ATP colored gray, F6P colored pink, and PGA colored purple 
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structure shown in Figure 2-3B is more flexible overall when compared to the apo and 
PGA-bound structures, with one exception being residues 156-162, which are across the 
allosteric interface from residue D12.   In the PGA-bound structure, residues 156-162 are 
in a loop conformation and in the substrate-bound and apo structures this region is in a 
helix conformation.  Residues 156-162 have higher B-factor values for the PGA-bound 
structure than the apo and substrate-bound structures.  The B-factors for the apo 
structure are not identical to either ligand bound structure, but the apo structure does 
appear to be more flexible than the PGA-bound structure and slightly less flexible than 
the substrate-bound structure. 
Figure 2-4 compares the F6P binding site of the apo BsPFK to the substrate-
bound and the PGA-bound forms of BsPFK.  Overall, the orientations of the residues in 
the active site for the apo structure appear to correspond better with the active site 
residues of the substrate-bound BsPFK than the PGA-bound BsPFK.  However, there are 
a few key residues with significant changes in orientation that have altered interactions 
that could not have been predicted without the apo BsPFK crystal structure.  For 
instance, Arg 72 interacts with the phosphate groups of ATP in the substrate-bound 
enzyme.  In the PGA-bound BsPFK where ATP is no longer bound, Arg 72 forms a salt-
bridge with Glu241 across the substrate-binding interface.  The orientation of Arg 72 in 
apo BsPFK is dramatically different from both liganded forms of BsPFK.  In apo 
BsPFK, Arg72 does not form a salt-bridge with Glu241. 
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A.      B. 
Figure 2-4  Overlay of residues in the Fru-6-P binding site of BsPFK. (A) Apo residues 
in blue, substrate-bound BsPFK residues in green, and Fru-6-P in black ball and stick.  
(B) Apo residues in blue and PGA-bound BsPFK residues in red.   All residues are 
labeled. 
 
 
 
His 249 is another residue that exhibits a difference in its orientation in the apo 
structure as compared to either liganded structure.  In the substrate-bound enzyme, His 
249 interacts with the phosphate group of F6P.  His 249 forms a hydrogen bond across 
the substrate binding interface with Glu 161 in the PGA-bound structure.  In the apo 
structure, His 249 forms a hydrogen bond with Tyr 164 across the binding interface.  
The breaking of the hydrogen bond between His 249 and Tyr 164 when PEP binds to the 
enzyme may be the basis for the substrate-binding interface being the weaker of the two 
interfaces.  Both wild-type and a tryptophan-shift mutant of BsPFK exhibit reversible 
dissociation of the tetramer along the active site interface in the presence of PEP.  
Perhaps the formation of a hydrogen bond across the substrate-binding interface between 
His 249 and either Tyr 164 or Glu 161 is important for tetramer stability.  Therefore, the 
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addition of PEP may cause a perturbation between these residues and in the quaternary 
structure of the enzyme to weaken the substrate binding interface.  Such weakening has 
been observed with BsPFK where it was demonstrated that the addition of PEP to the 
enzyme induced the dimers of BsPFK to exchange along the substrate-binding interface 
(133). 
Figure 2-4 shows the relative positions of Glu 161 and Arg 162 in the active sites 
of the substrate-bound, PGA-bound, and apo crystal structures.  In the substrate-bound 
BsPFK structure, the positively charged Arg 162 interacts with the negatively charged 
phosphate group of F6P, and in the PGA-bound structure, the negatively charged Glu 
161 replaces Arg 162, thereby repelling F6P from the active site.  These structural 
features were used to rationalize the MWC model for BsPFK (101).  Prior to this, the 
apo BsPFK structure was presumed to be in the T-state; therefore, according to 
assumptions made based on the MWC model, Glu 161 should be poised in the active site 
of the apo crystal structure ready to repel F6P (120, 121).  However, Arg 162 is in the 
active site of the apo BsPFK crystal structure, with the apo positions of both Arg 162 
and Glu 161 matching quite well with the substrate-bound positions (Figure 2-4). 
Figure 2-5 compares the effector binding site of apo BsPFK to the substrate-
bound form and the PGA-bound form, respectively.  The orientation of the 8-H loop 
(residues 213-215) in the apo structure resembles that of the substrate-bound enzyme, 
except the loop is slightly more open in the apo structure.  Arg 211 is not well ordered in 
the apo structure and can only be visualized in subunit D, where the orientation of Arg 
211 is significantly different from both of the liganded structures.  Arg 211 interacts with 
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A.         B. 
Figure 2-5  Overlay of residues in the effector binding site of BsPFK. (A) Apo residues 
in blue, substrate-bound BsPFK residues in green, and ADP in gray ball and stick.  (B) 
Apo residues in blue, PGA-bound BsPFK residues in red, and PGA in purple ball and 
stick. 
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the α-phosphate of ADP in the substrate-bound BsPFK.  In the PGA-bound BsPFK, Arg 
211 interacts with the carboxylate group of PGA.  Arg 211 also interacts with the 
backbone carbonyl oxygen of Ile 320 in both of the liganded structures.  However, in the 
apo BsPFK structure, Arg 211 is positioned so that it interacts only with a water 
molecule.  Therefore, Arg 211 no longer binds with the backbone oxygen of Ile 320.  
The position of Glu 187 also shows significant deviation relative to both substrate-bound 
and PGA-bound enzymes.  In the substrate-bound structure, the R group of Glu 187 is 
coordinated to the magnesium ion of ADP and interacts with Lys 213.  In the PGA-
bound structure, the R group rotates away from the ligand and interacts with Lys 213 
and Ser 216.  However, in the apo structure, Glu 187 forms a hydrogen bond with a 
water molecule and no other residue. 
 
Discussion 
When considering the mechanistic basis of allosteric behavior in enzymes, it is 
important to interpret both the structural and the thermodynamic characteristics of the 
enzyme simultaneously.  The two-state model that has been proposed to explain the 
allosteric mechanism for BsPFK is based on the differences between the crystal 
structures of the substrate-bound and the PGA-bound enzymes (101) and structure alone 
does not address the issue of reciprocity.  Reciprocity acknowledges that whatever 
affects an allosteric ligand has on the binding of the substrate; the same effect is felt by 
the allosteric ligand when the substrate binds.  There is no apparent structural reciprocity 
seen in the active and effector binding sites of BsPFK.  In addition, it is not apparent 
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whether the structural differences seen between the two liganded species are a 
consequence of ligand binding the enzyme or are attributable to the inherent nature of 
the enzyme.  An apo BsPFK structure allows for the assessment of actual ligand-induced 
effects on the structure of the enzyme and thereby serves as an important reference 
structure. 
The importance of the apo structure of BsPFK is further underscored when 
considering the origin of the coupling free energy between an effector (X) and a 
substrate (A) that quantifies both the nature and the magnitude of a K-type allosteric 
effect.  The coupling free energy, or ∆Gax, is determined using the following equation 
(94, 95): 
 ∆Gax=-RTlnQax (2-1) 
where Q
ax
 is the coupling constant that is given by: 
 Q
ax
=
Kia
°
Kia
∞ =
Kix
°
Kix
∞ . (2-2) 
Kia
°  and
 
Kia
∞ are the dissociation constants for A in the absence and saturating presence of 
X, respectively, andKix
°  and Kix
∞ are the dissociation constants for X in the absence and 
saturating presence of A, respectively.  Therefore, if ∆Gax is negative (or Qax > 1), then 
the allosteric effector is an activator and if ∆Gax is positive (or Qax < 1), the allosteric 
effector is an inhibitor.  When ∆Gax is equal to zero (or Qax = 1) there is no allosteric 
effect.  The above definitions reveal that Q
ax
 is the equilibrium constant for the 
following disproportionation equilibrium: 
 XE + EA 
𝑄𝑎𝑥
 XEA + E (2-3) 
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where E is the apo enzyme, EA is the enzyme bound to the substrate, XE is the enzyme 
bound to the effector, and XEA is the ternary complex formed when both substrate and 
effector are bound.  This equilibrium depicts the different forms that BsPFK can assume 
in the presence of substrate and allosteric effector.  All four enzyme species are involved 
in determining the value of Q
ax
.  The two-state model is based exclusively on a 
consideration of the XE and the EA forms that describes only the left side of the 
disporportionation equilibrium and ignores the entire right side; and therefore does not 
adequately describe the coupling free energy of the reaction. 
The four species of enzyme that contribute to the allosteric mechanism have free 
energies of formation of their own.  In other words, the coupling free energy can be 
defined by subtracting the free energy of formations of the EA and XE from that of XEA 
and E (98): 
                                           ∆Gax= GXEA+GE - GEA+GXE .         (2-4) 
This equation can be converted to the following equivalent expression: 
                               ∆Gax= GXEA-GE -  GEA-GE + GXE-GE  .       (2-5) 
Further simplification of the above equation can be done by denoting the differences in 
the parenthesis with a 𝛿 such that: 
                                             ∆Gax=δGXEA- δGEA+δGXE . (2-6) 
With the above expression it is clear that the free energy of the apo form of the enzyme 
is crucial to the overall coupling free energy of the allosteric reaction.  Note that ΔG and 
𝛿G are two different expressions, where ΔG considers the free energy implications of 
the free ligand and 𝛿G does not, hence the reason for the different symbols. Given the 
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fact that the free energy of the apo enzyme must be subtracted from each enzyme form 
addresses the importance of the apo structure.  The structure of the apo BsPFK allows 
for the structural perturbations that occur from each ligand binding event to be observed.  
Therefore, it may be possible to determine some of the structural contributions to the 
free energy of binding of the liganded forms of the enzyme.  
 In order to fully describe ∆Gax in terms of structure, all four structures of the 
enzyme are needed. The above expression demonstrates the necessity of obtaining as 
much information as possible about all forms of the enzyme, particularly the form bound 
to both F6P and PEP simultaneously (XEA).  The difference between the free energy of 
the XEA form and the combined free energies of the binary complexes is what 
determines the actual coupling free energy.  The model adopted by Schirmer and Evans 
describes the allosteric inhibition of BsPFK by using only two of the four species, and 
virtually ignores the E and XEA forms (101).   Although the structure of XEA has not 
yet been determined, we are now one step closer to understanding the structural 
implications of the allosteric inhibition of BsPFK with the addition of the apo BsPFK 
structure. 
Strictly using a structurally based model to describe an allosteric mechanism 
tends to oversimplify the regulation of the enzyme. However, reconciling the structures 
of BsPFK with the experimentally measured thermodynamic parameters of the enzyme 
will lead to understanding the structure-function relationship of the allosteric 
mechanism.  With the addition of the apo BsPFK structure, there are now more relevant 
structures to the allosteric regulation of BsPFK than any other PFK enzyme.  More 
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importantly, the apo BsPFK structure serves as a necessary reference structure for 
comparison to the liganded structures.  The obvious next step would be to obtain the 
structure of the XEA form of BsPFK.  Along with the thermodynamic data already 
collected on the XEA form of BsPFK, this structure would go a long way in helping us 
better understand the basis for allosterism in BsPFK. 
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CHAPTER III 
REDEFINING THE ROLE OF THE QUATERNARY SHIFT IN BACILLUS 
STEAROTHERMOPHILUS PHOSPHOFRUCTOKINASE 
 
 Phosphofructokinase (PFK) is a highly regulated enzyme that catalyzes the first 
committed step of glycolysis.  PFK transfers the γ-phosphate of Mg-ATP to fructose-6-
phosphate (F6P) producing fructose-1, 6-bisphosphate and Mg-ADP.  The PFK from the 
moderate thermophile, Bacillus stearothermophilus (Bs), is a homotetramer of 34 KDa 
per monomer that forms a rigid dimer of dimers which consists of two unique dimer-
dimer interfaces.  The substrate interfaces comprise the binding sites for F6P, for which 
there are four identical binding sites per homotetramer.  The effector interfaces contain 
the binding sites for the allosteric ligands, for which there are four identical effector 
binding sites per homotetramer.  The allosteric binding sites are capable of binding 
either MgADP or phosphoenolpyruvate (PEP).  For BsPFK, MgADP serves as a very 
weak activator and PEP is a very strong inhibitor.  Both PEP and MgADP alter the 
affinity BsPFK has for F6P without changing the enzyme‟s maximal activity; therefore, 
both allosteric ligands are considered to be K-type effectors. 
 The regulation and structure of BsPFK has been the subject of study for over 
three decades (120).  Ever since 1990, with the publication of Schirmer and Evan‟s 
paper titled “Structural basis for the allosteric behavior of phosphofructokinase” (101), 
the structural basis for the allosteric nature of BsPFK has been used as an example of 
allosteric regulation (102, 103).  Schirmer and Evans compared the crystal structures of 
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the substrate bound BsPFK and the inhibitor bound BsPFK.   The substrate bound 
BsPFK consists of the enzyme bound to F6P and MgADP in all four substrate binding 
pockets and MgADP bound in all four effector binging sites (accession code 4PFK) 
(121).  The inhibitor bound BsPFK consists of the enzyme bound to the PEP analog, 
phosphoglycolate (PGA), in all four effector binding sites (accession code 6PFK) (101).  
When the crystal structures of the substrate bound and the PGA bound enzymes are 
compared there is a conformational change that occurs in the PGA bound BsPFK.  The 
conformational change includes a difference in the quaternary structures of the two 
enzyme forms.  The quaternary structure of the inhibitor bound BsPFK has undergone a 
7° rotation about the substrate binding interface, termed the quaternary shift, when 
compared to the substrate bound BsPFK.  The conformational change also includes the 
movement of residues E161 and R162 in the active site.  When F6P is bound to the 
enzyme, the positively charged R group of R162 interacts with the negatively charged 
phosphate group of F6P.  In the PGA bound structure, R162 is replaced by the 
negatively charged R group of E161.  Given the structural differences seen between the 
substrate bound and inhibitor bound structures of BsPFK, Schirmer and Evans proposed 
the concerted transition or Monod, Wyman, Changeux (MWC) model (87, 101) to 
describe the allosteric behavior of BsPFK (101).  More specifically, they proposed that 
the allosteric inhibition of BsPFK was due to the quaternary shift and the switching of 
E161 and R162 in the active site (101). 
 In the years since Schirmer and Evans introduced their model, several studies 
have suggested that the MWC model is insufficient in describing the mechanism of 
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inhibition for BsPFK (104-106).  Kimmel and Reinhart measured the thermodynamic 
parameters of active site mutants of BsPFK.  They showed that the switching of E161 
and R162 in the active sites of the substrate bound and PGA bound structures of BsPFK 
did not adequately explain the allosteric inhibition of the enzyme by PEP (104).  The 
study by Kimmel and Reinhart is supported by the findings of Braxton, et. al. in which 
MgADP, a weak activator of BsPFK at moderate temperatures, becomes an allosteric 
inhibitor at temperatures below 16°C (105).  A key component of the MWC model is 
that allosteric activators and inhibitors bind to distinct forms of the enzyme.  
Accordingly, MgADP would stabilize the active site of BsPFK so that F6P can more 
readily bind to the enzyme.  However, Braxton, et. al. showed that the structure alone 
could not explain how MgADP becomes an inhibitor at lower temperatures (105).  
Braxton et. al. also pointed out that attributing the allosteric nature of BsPFK to 
structural perturbations alone addressed the enthalpic component of the coupling free 
energy, but ignored the entropic component completely [4].  Tlapak-Simmons and 
Reinhart addressed the differences in the kinetics and allosteric properties of BsPFK 
with PEP, the native allosteric inhibitor of BsPFK, and PGA, the PEP analog that is 
present in the inhibited form of BsPFK (106).  Schirmer and Evans reasoned that the 
PGA structure would exhibit the same structural characteristics as the PEP structure 
since the two components are structurally similar (101).  Tlapak-Simmons and Reinhart 
showed that while PEP and PGA are qualitatively the same, they are quantitatively 
different (106).  The aforementioned studies provide evidence that does not support the 
model asserted by Schirmer and Evans.  However, the role of the quaternary shift in 
60 
 
 
BsPFK is still questionable.  Schirmer and Evans delegate the allosteric inhibition of 
BsPFK to the switching of E161 and R162 in the active site and the quaternary shift.  
The former has already been addressed by Kimmel and Reinhart (104), the latter is 
addressed in the following study. 
A sequence comparison of all available bacterial ATP-dependent PFKs 
(approximately 150 amino acid sequences) reveals that only 14 residues are completely 
conserved.  Of the 14 residues, seven are glycines, two are involved in substrate binding 
or catalysis, and five do not directly bind to any ligand.  Of the two residues that are 
necessary in binding a ligand, R252 binds directly to the 6-phosphate group of F6P and 
D127 acts as a catalytic base.  The five 100% conserved residues that do not directly 
bind to any ligand are D12, N17, P123, D129, and T156.  According to the F6P bound 
BsPFK crystal structure, D12 interacts with R252 within its own monomer and with 
T156, S159, and H160 in the adjacent monomer across the substrate-binding interface 
(Figure 3-1A).  In the PGA bound BsPFK structure, residues 156-160 (last turn of helix 
6) adopt a loop conformation that results in D12 potentially interacting with only T158 
across the substrate-binding interface.  Therefore, in the inhibitor bound structure, the 
hydrogen bond between D12 and R252 no longer exists as it did in the substrate bound 
structure (Figure 3-1B).  N17 forms hydrogen bonds with backbone atoms of residues 
within its own monomer, bonds that remain unchanged in the substrate bound and 
inhibitor bound forms.  P123 and D129 form no apparent hydrogen bonds with any 
residues.  As indicated before, T156 forms a hydrogen bond with D12 in the adjacent 
monomer in the substrate bound enzyme.  When PGA is bound to BsPFK, T156 no 
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A.         B.  
Figure 3-1  Crystal structure of D12 region in wild-type BsPFK.  (1A) Crystal structure 
of wild-type BsPFK bound to F6P and MgADP(121).  (1B)  Crystal structure of wild-
type BsPFK bound to PGA (101). Distances are indicated and are in Å. 
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longer interacts with D12; instead T156 forms a hydrogen bond with the OH group of 
Y164 within its own monomer.  Therefore, out of all of the completely conserved 
residues, D12 and T156 are the only two residues that do not directly bind to any ligand, 
are located along a dimer-dimer interface, and form hydrogen bonds that dramatically 
change depending on whether substrate or inhibitor is bound.  D12 is the only residue of 
the group that can interact with up to four residues (T156, S159, H160, and R252) when 
the substrate is bound to the enzyme, three of these residues belonging to helix 6 in the 
adjacent monomer.  In addition, D12 continues to interact with loop 6F across the 
substrate-binding interface when PGA is bound.   
The highly conserved nature and lack of direct ligand interactions of D12 and 
T156 is an intriguing facet of the amino acid sequence of bacterial PFKs.  Furthermore, 
the residues D12 potentially interacts with when the enzyme is in the substrate bound 
form, S159 and H160, are both 96% conserved among the ATP-dependent PFKs 
compared.  These four residues are located along the substrate binding interface.  This 
dimer-dimer interface is the same interface that undergoes the quaternary shift in the 
PGA bound structure of BsPFK.  In an attempt to understand the role of these highly 
conserved residues, alanine scanning mutagenesis was performed on D12 and the 
residues D12 potentially interacts with across the interface (T156, T158, S159, and 
H160).  Previous work performed by Ortigosa, et. al. noted the importance of D12A in 
experiments designed to isolate each of the four unique heterotropic interactions found 
in BsPFK (134).  The D12A mutation was made in concert with other mutations; 
therefore, the characteristics of the single mutant were never fully investigated.  The 
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following data describes the kinetic and structural characteristics of the variants D12A 
BsPFK and T156A BsPFK.  In addition, the kinetic and coupling parameters of T158A, 
S159A, and H160A are described.  The mutations, D12A and T156A, both significantly 
alter the binding of PEP and F6P without appreciably changing the coupling constant 
when compared to wild-type BsPFK.  In addition, two crystal structures of D12A BsPFK 
and one crystal structure of T156A BsPFK are introduced.  Figure 3-2 compares the D12 
region of apo BsPFK (Figure 3-2A), substrate bound BsPFK (Figure 3-2B), PGA bound 
BsPFK (Figure 3-2C), apo D12A BsPFK (Figure 3-2D), PEP bound D12A BsPFK 
(figure 3-2E), and PEP bound T156A BsPFK (Figure 3-2F).  Both the apo and PEP 
bound structures of D12A BsPFK and the PEP bound structure of T156A BsPFK are in 
the quaternary shifted position characteristic of the PGA bound wild-type BsPFK 
structure.  The fact that D12A BsPFK and T156A BsPFK crystal structures are in the 
quaternary shifted position and still experience allosteric inhibition by PEP brings to 
question the traditional role of the quaternary shift proposed by Schirmer and Evans. 
  
64 
 
 
A.    B.    C. 
   
D.    E.    F. 
    
Figure 3-2  Comparison of the D12 region between wild-type and variants of BsPFK 
crystal structures.  (A) Wild-type apo. (B) Wild-type substrate bound. (C) Wild-type 
PGA bound. (D) D12A apo.  (E) D12A PEP bound.  (F) T156A PEP bound.  Wild-type 
BsPFK is red ribbon, D12A BsPFK is grey ribbon, and T156A is green ribbon.  Residue 
D12 (or D12A) is blue, T156 (or T156A) is purple, T158 is pink, S159 is orange, and 
H160 is green. ADP is light blue, Fru-6-P is light green, PGA is yellow, and PEP is gold. 
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Materials and Methods 
Materials 
All chemical reagents used in buffers, protein purifications, and enzymatic assays 
were of analytical grade, purchased from Sigma-Aldrich (St. Louis, MO) or Fisher 
Scientific (Fair Lawn, NJ).  Creatine kinase and the ammonium sulfate suspension of 
glycerol-3-phosphate dehydrogenase were purchased from Roche (Indianapolis, IN).  
The ammonium sulfate suspensions of aldolase and triosephosphate isomerase, and the 
sodium salts of phosphocreatine, ATP, and PEP were purchased from Sigma-Aldrich.   
The coupling enzymes were extensively dialyzed against 50 mM MOPS-KOH, pH 7.0, 
100 mM KCl, 5 mM MgCl2, and 0.1 mM EDTA before use.  The sodium salt of F6P 
was purchased from Sigma-Aldrich or USB Corporation (Cleveland, OH).  NADH and 
DTT were purchased from Research Products International (Mt. Prospect, IL) and the 
crystallization materials were purchased from Hampton Research (Aliso Viejo, CA).  
DE52 and Memetic Blue 1 resin used in protein purifications were purchased from 
Whatman (Maidstone, England) and Promatic BioSciences (Rockville, Maryland), 
respectively.  Site-directed mutagenesis was performed using the QuikChange Site-
Directed Mutagenesis System from Stratagene (La Jolla, CA).  Oligonucleotides were 
synthesized and purchased from Integrated DNA Technologies, Inc (Coralville, IA).   
DNA modifying enzymes and dNTP‟s were purchased from Stratagene (Cedar Creek, 
TX), New England Biolabs (Ipswich, MA), or Promega (Madison, WI).  Deionized 
distilled water was used throughout. 
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Site-directed Mutagenesis 
The plasmid pBR322/BsPFK (123) contains the gene for BsPFK behind the 
native Bacillus stearothermophilus promoter and was received as a generous gift from 
Simon H. Chang (Louisiana State University).   Mutagenesis was performed following 
the QuikChange Site-Directed Mutagenesis protocol.  Two complementary 
oligonucleotides were used to make the mutant genes and only the template oligo is 
shown below.  The underlined bases designate the codon for the alanine that replaced the 
specific residue indicated. 
D12A:   G TTG ACA AGC GGC GGC GCC TCG CCG GGA ATG  
T156A:  C GAC AAA ATC CGC GAC GCC GCG ACG TCG  
T158A:  CGC GAC ACG GCG GCC TCG CAC GAG 
S159A:  GAC ACG GCG ACG GCC CAC GAG CGG AC 
H160A:  CG GCG ACG TCG GCC GAC CGG ACG TAC G 
Wild-type and all mutant BsPFKs were expressed in  E.coli RL257 cells (124), which is 
a strain of E.coli lacking both the PFK-1 and PFK-2 genes.  
 
Protein Purification for Wild-type, T158A, S159A, and H160A BsPFK 
The purification of both wild-type and variant BsPFKs was performed as 
described previously, with a few modifications (125).  RL257 cells containing the 
appropriate plasmid were grown at 37°C for 16-18 hours in LB (Lysogeny Broth) 
ampicillin (Tryptone 10 g/L, yeast extract 5 g/L, and Sodium Chloride 10 g/L, ampicillin 
100 ug/ml).  Cells were pelleted and frozen for at least 12 hours.  The cells were 
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resuspended in purification buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0) and 
sonicated at 0°C in 15 second pulses for 8 minutes with a Fisher 550 Sonic 
Dismembrator.  The crude lysate was centrifuged using a Beckman model J2-21 
centrifuge equipped with a JA20 rotor at 22,500 x g for one hour at 4°C.  The clear 
supernatant was heated at 70°C for 15 minutes, cooled on ice for 15 minutes, and 
centrifuged as before.  The diluted supernatant for the wild-type protein was loaded onto 
a Mimetic Blue 1 column.  The column was equilibrated with purification buffer before 
loading the supernatant containing the protein of interest.  The column was washed with 
at least 5 bed volumes of purification buffer and the enzyme was eluted with a 0 – 1 M 
NaCl gradient.  Enzyme containing fractions were pooled and dialyzed into 20 mM tris-
HCl pH 8.5 and loaded onto a Pharmacia Mono-Q anion exchange column.  The enzyme 
was eluted with a 0 – 1 M NaCl gradient and PFK containing fractions were combined, 
concentrated, then dialyzed into EPPS Buffer ( 50 mM EPPS, 10 mM MgCl2, 100 mM 
KCl, 0.1 mM EDTA pH 8.0).  Concentrated enzyme was stored in EPPS buffer at 4°C.  
The final enzyme was determined to be pure by SDS-PAGE and the concentration was 
ascertained using the absorbance at 280 nm (ε = 18910 M-1cm-1(126)).   
 
Protein Purification for D12A and T156A BsPFK 
Protein purification for D12A BsPFK and T156A BsPFK were carried out as 
described above, with the following exceptions.  T156A BsPFK lost a significant 
amount of activity during the heating step unless 1 mM F6P was added to the 
supernatant before heating.  F6P was not added to any other buffer for the duration of the 
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purification for T156A BsPFK.  D12A BsPFK and T156A BsPFK did not respond to the 
Mimetic Blue 1 resin the same as wild-type so that the supernatant was loaded onto a 
DE52 column.  The DE52 column was prepared and treated the same as the Mimetic 
Blue 1 column.       
 
Crystallization and Data Collection 
The apo and the PEP bound D12A BsPFKs and the T156A BsPFK were 
crystallized using the hanging drop vapor diffusion method at 16°C.  Apo D12A BsPFK 
was obtained through extensive dialysis of the mutant enzyme in EPPS buffer containing 
50 mM EPPS, 10 mM MgCl2, 100 mM KCl, 0.1 mM EDTA, 10 mM F6P pH 8.0 
followed by extensive dialysis in F6P free EPPS buffer.  The crystallization condition 
for the Apo D12A BsPFK structure was a 4 μl drop consisting of 2 μl of solvent (0.2 M 
magnesium chloride hexahydrate, 0.1 M tris hydrochloride pH8.5, and 30% w/v 
polyethylene glycol 4,000) and 2 μl of protein (stock concentration of apo D12A BsPFK 
was 35 mg/mL stored in EPPS buffer).  PEP bound D12A BsPFK was obtained through 
purification of the enzyme as directed above.  The PEP bound to the enzyme is 
indigenous Escherichia coli PEP.  The crystallization condition for the PEP bound D12A 
structure was a 6 μl drop consisting of 2 μl of solvent (0.1 M sodium citrate tribasic 
dehydrate pH 5.6, 20% v/v 2-propanol, 20% w/v polyethylene glycol 4,000) and 4 μl of 
protein (stock concentration of D12A BsPFK was 34 mg/mL stored in EPPS buffer).  
The crystallization condition for the T156A BsPFK structure was either 2 μl of solvent 
(0.1M HEPES sodium pH 7.5 and 1.4 M Sodium citrate tribasic dehydrate) and either 3 
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or 4 μl protein (stock concentration of T156A BsPFK was 13 mg/ml).  The T156A 
BsPFK crystal structure is bound to four PEP molecules, just as the PEP bound D12A 
BsPFK.  And just as the D12A BsPFK is bound to the indigenous Escherichia coli PEP, 
so is the T156A BsPFK. Numerous attempts were made to crystallize T156A BsPFK 
without the inhibitor bound; however, none were successful.  In addition, attempts were 
made to crystallize the variants T158A, S159A, and H160A BsPFKs.  All proteins 
yielded crystals, but the quality of the crystals were insufficient and did not produce 
quality data. 
Within 2-3 days crystals formed for both species (D12A and T156A BsPFK) of 
enzyme.  Variant BsPFK crystals were briefly soaked in cryogenic mother liquor 
containing 30% ethylene glycol and then flash-frozen in a liquid N2 stream at 100 K.  
Diffraction data for the apo and PEP bound D12A BsPFK crystals were collected on an 
Advanced Photon Source (APS) beam line 23-ID (insertion device) using a MAR 300 
CCD detector (MarMosaic from Marresearch- Charged Coupled Device) (Rayonix LLC, 
Evanston, IL).  The high resolution data of T156A BsPFK was collected at beamline 19-
ID on an Area Detector Systems Corporation Q315 area detector at the Advanced 
Photon Source, Argonne National Laboratory.  The HKL2000  program package (HKL 
Research, Inc., Charlottesville, VA) (128) was used for integration and scaling of the 
PEP bound D12A crystals, while d*TREK (Rigaku Americas, Woodlands, TX) was 
used for integration and scaling of the apo D12A and T156A crystals (128, 135).  Data 
collection details are summarized in Table 3-1. 
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Table 3-1  Data collection and refinement statistics for apo and PEP bound D12A 
BsPFK structures
b 
 
Data set D12A apo  D12A-PEP T156A-PEP 
Unit cell (Å)  a = 96.05 a=96.65 a=96.405 
 b = 112.66 b=112.97 b=111.575 
 c = 129.73 c=131.04 c=129.448 
Space group  P212121  P212121 P212121 
Number of molecules per asymmetric unit (Z)  4 monomers 4 monomers 4 monomers 
Resolution  (Å)   40-2.3 65-2.0 45-2.5 
Completeness (%)  100.0(100.0) 97.0(78.2) 100.0(100.0) 
I/ I  12.2(3.1) 13.3(2.7) 36.49 (5.68) 
Rmerge 11.5 (46.0) 5.3(38.9) 10.6 (46) 
Refinement     
Resolution  (Å)  40-2.3 50-2.00 45-2.5 
Reflections (working/free)  63108 (3204) 89745(4715)  
R (%)  20.07 18.86 16.6 
Rfree(%)  25.39 23.48 23.78 
Number of protein atoms/number of waters  9517/329 9574/626 9429/312 
 
Average B factor (Å
2
)  48.41 28.96 50.5 
Average B factor for water molecules (Å
2
)  44.21 43.53 53.1 
Rmsd Bond length (Å)  0.004 0.012 0.005 
Rmsd Bond angles (degrees) 0.517 1.355 0.637 
Ramachandran statistics     
Most favored  97.3% 97.2% 97.79% 
Allowed  2.5% 2.8% 0.08% 
a
 Values in parentheses are for high resolution shells.  Rsym = h i|Ihi - Ih |/ h iIhi, 
where Ihi is the ith observation of the reflection h, whereas <Ih> is the means intensity of 
reflection h. 
b
 Rcryst = |Fo| - |Fc|/|Fo|. Rfree was calculated with a fraction (5%) of 
randomly selected reflections excluded from refinement.  
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Structure Determination and Refinement 
Molecular replacement program PHASER (University of Cambridge, UK)  (129) 
was used to solve the structure of the apo and PEP bound BsPFKs using the phosphate 
bound crystal structure of BsPFK (PDB accession code 3PFK) (121) with waters and 
ions removed as the search model.  Rigid body refinement followed by simulated 
annealing refinement at 5000K was carried out using Phenix (Python-based Hierarchical 
Environment for Integrated Xtallography, Berkely, CA) (130) for the apo structure while 
CCP4 Refmac (York Structural Biology Laboratory, University of York, Heslington, 
UK) with TLS refinement (translation, libration and screw-rotation) (Science and 
Technology Facilities Council, Daresbury, UK) were used for the refinement of the PEP 
bound protein(136, 137).  Subsequently, refinement was carried out in alternating cycles 
of manual model building in COOT (Crystallographic Object-Orientated Toolkit, 
Oxford, UK) (131) followed by refinement until the R-factors converged. The 
stereochemistry of the final models of the BsPFK enzymes were verified by MolProbity 
(Duke University, Durham, NC) (132).   
 
Kinetic Assays 
Activity measurements for PFK were carried out in a 0.6 mL reaction volume of 
EPPS buffer containing 50 mM EPPS, 10 mM MgCl2, 100 mM KCl, 0.1 mM EDTA, 2 
mM DTT, 0.2 mM NADH, 3 mM ATP, 250 μg aldolase, 50 μg of glycerol-3-phosphate 
dehydrogenase, 5 μg of triosephosphate isomerase, 40 μg/mL of creatine kinase and 4 
mM phosphocreatine at pH 8.0 and 25 °C.  F6P and PEP were added at varied 
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concentrations as indicated.  Assays were started by the addition of 6 μL of appropriately 
diluted PFK and the reaction was monitored as the absorbance at 340 nm decreased over 
time.  Dilution of T156A BsPFK in EPPS buffer resulted in significant loss of activity; 
therefore, all dilutions of T156A BsPFK were done in EPPS buffer containing 1 mM 
F6P.  The addition of F6P resulted in T156A BsPFK remaining stable throughout the 
duration of the assays.  The rate of the reaction was measured on Beckman Series 600 
spectrophotometers.  One unit of PFK activity is described as the amount of enzyme 
needed to produce 1 μmol of F16BP per minute. 
 
Data Analysis 
Data were fit to the following equations using the least-squares fitting analysis of 
Kaleidagraph software (Synergy).  Initial velocity activities, that were measured in the 
kinetic assays where the F6P concentration was saturable, were fit to the Hill equation 
(138): 
                                                            
v
ET
=
Vmax A 
nH
K
1 2 
nH +[A]
nH
                                           (3-1) 
where v is the initial rate, ET is the total enzyme active site concentration, [A] is the 
concentration of the substrate F6P, Vmax is the maximal velocity, K1/2 is the 
concentration of F6P that gives one-half the maximal specific activity, and nH is the Hill 
coefficient.  In the D12A BsPFK kinetic assays, the K1/2 is unattainable at higher 
concentrations of inhibitor because the F6P titration does not reach saturation; therefore, 
the data were fit to the following equation: 
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v
ET
=
kcat
K1/2
 A .          (3-2) 
The allosteric responses of BsPFK to PEP were quantified by plotting either the K1/2 
from Equation 3-1 or the reciprocal of Vmax K1/2  from equation 3-2 versus the PEP 
concentration and  fitting these data to the following equation (96): 
                                                      Ka=Kia
° Kiy
°
+ Y 
Kiy
°
+Qay Y 
        (3-3) 
where Ka is equal to K1/2 when data were fit to Equation 3-1 or K1/2 Vmax  when data 
were fit to Equation 3-2, [Y] is the concentration of the inhibitor PEP, Kia
°  is the 
dissociation constant for F6P in the absence of PEP, Kiy
°  is the dissociation constant for 
PEP in the absence of F6P, and Q
ay
 is the coupling coefficient which describes both the 
nature and the magnitude of the allosteric response (96, 99).  Q
ay
 describes an inhibitor 
when it is less than one and an activator when it is greater than one.  There is no 
allosteric response when Q
ay
 equals to one.   
 
Results 
BsPFK, like many oligomeric enzymes, contains ligand binding sites that lie 
along the interface of two subunits, such that every active site and effector site is 
comprised of residues from adjacent monomers.  BsPFK contains four substrate binding 
sites that are formed along one dimer-dimer interface (substrate interface) and four 
effector binding sites formed along the other dimer-dimer interface (allosteric interface).   
Located in the C-4a loop, along the active site interface, is the completely conserved 
amino acid D12, which does not directly interact with any ligand.  Comparison of the 
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substrate bound and apo wild-type BsPFK crystal structures reveals that an intra-subunit 
hydrogen bond exists between R252 (R252 directly binds to the 6-phosphate of 
F6P(101)) and D12 regardless of whether or not F6P is bound (Figure 3-2A and 3-2B).  
According to the PGA bound structure, the R252-D12 interaction is lost when the 
inhibitor analog is bound to the enzyme (Figure 3-2C).  The relationship between these 
two residues was first manipulated by making the double mutant R252A/D12A in order 
to create specific hybrids in BsPFK (134).  Interestingly, the specific activity of the 
double mutant and the single mutant, R252A, are comparable to the wild-type enzyme 
(125, 134).   However, the specific activity of D12A BsPFK, as shown in Figure 3-3, is 
almost 7 fold lower than wild-type BsPFK.   Equation 3-1 was used to fit both the wild-
type and the variants data.  The apparent dissociation of F6P (K1/2) for D12A BsPFK is 
augmented by 50-fold compared to that of wild-type, which makes performing complete 
F6P titrations at high concentrations of inhibitor impossible due to the inability of the 
enzyme to be fully saturated by substrate.  The F6P binding of H160A BsPFK is only 
diminished 2-fold when compared to wild-type; however, this small augmentation in 
substrate binding was significant enough to necessitate a different approach to obtaining 
kinetic data.  Therefore, in an attempt to measure the nature and magnitude of the 
allosteric effect between F6P and PEP for D12A BsPFK and H160A BsPFK, only data 
in the linear region of the F6P titration curves were fit to Equation 3-2.  This linear   
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Figure 3-3  Specific activity versus F6P concentration for wild-type and D12A BsPFK.  
Wild-type BsPFK is represented by red circles and D12A BsPFK is represented by blue 
squares.  Solid lines represent the best fit of the data to Equation 3-1. 
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Figure 3-4  Specific activity versus F6P concentration under first-order conditions for 
wild-type and D12A BsPFK.  Wild-type BsPFK is in circles and red.  D12A BsPFK is in 
squares and blue.    Solid lines represent the best fit of the data to Equation 3-2.   
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region, shown for both wild-type and D12A in Figure 3-4, is indicative of the first 
binding event of F6P to the enzyme, assuming that the hill number remains relatively 
constant.   
Figure 3-5 compares plotting K1/2 or Km/Vmax versus the PEP concentration for 
wild-type BsPFK in order to demonstrate the efficacy of using Km/Vmax in Equation 3-3.  
The apparent dissociation constant for PEP in the absence of F6P and the coupling 
parameter, Qay, for both methods are within error of each other.  The apparent 
dissociation constant for F6P is the only parameter of Equation 3-3 that is not 
comparable between the two techniques; however, by simply fitting Equation 3-1 to a 
F6P titration curve in the absence of PEP and taking the K1/2 from this fit can the Kia
°  be 
approximated.  Figure 3-6 illustrates the Km/Vmax versus the PEP concentration for wild-
type, D12A, and H160A BsPFKs.  Table 3-2 compares the kinetic and coupling 
parameters of wild-type, D12A, and H160A BsPFKs.  D12A BsPFK has a dissociation 
constant for F6P, Kia
° , of 1.4±0.1 mM, which is almost a 50-fold increase in substrate 
binding affinity compared to wild-type BsPFK.  In addition, D12A BsPFK has a 
dissociation constant for PEP, Kiy
° , of 0.45 ± 0.01 uM, which is a 100-fold increase in 
binding affinity compared to wild-type BsPFK.  Most striking, however, is that the 
coupling parameter for D12A is remarkably similar to that of wild-type. 
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Figure 3-5  K vs. PEP concentration plot comparing Km/Vmax and K1/2 methods for wild-
type BsPFK.  Data points from Km/Vmax method in red circles.  Data points from K1/2 
method in orange squares.  Solid lines represent the best fit to Equation 3-3. 
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Figure 3-6  Influence of PEP on the Km/Vmax of wild-type, D12A, and H160A BsPFKs.  
Wild-type is represented by red circles, D12A is represented by blue squares, and 
H160A is represented by open green circles.  Solid lines represent the best fit to 
Equation 3-3.  
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Table 3-2  Steady-state kinetic and coupling parameters for wild-type, D12A, and 
H160A BsPFKs 
 
 Wild-type D12A H160A 
Specific Activity (U/mg) 163 ± 3 24 ± 1 70 ± 2 
Kia
°  (mM) 0.030 ± 0.002 1.4 ± 0.1 0.056 ± 0.002 
Kiy
°  (mM) 0.060 ± 0.004 0.00045 ± 0.00001 0.001 ± 0.00005 
Qay 0.002 ± 0.0003 0.003 ± 0.0001 0.000005± 0.0000004 
 
 
 
Table 3-3  Steady-state kinetic and coupling parameters for variant BsPFKs 
 T156A T158A S159A 
Specific Activity (U/mg) 50 ± 3 70 ± 3 140 ± 4 
Kia
°  (mM) 0.52 ± 0.005 0.017 ± 0.0005 0.025 ± 0.003 
Kiy
°  (mM) 0.0021 ± 0.00004 0.098 ± 0.004 0.012 ± 0.001 
Qay 0.002 ± 0.0007 0.009 ± 0.0003 0.0005 ± 0.00006 
 
 
 
Given the remarkable binding and coupling characteristics of D12A BsPFK, the 
same kinetic and coupling parameters for T156A, T158A, S159A, and H160A were 
measured.  Figure 3-6 and Figure 3-7 compare the Km/Vmax or the K1/2, respectively, 
versus the PEP concentration for wild-type and all of the variants of BsPFK.  In addition, 
Tables 3-2 and 3-3 display the kinetic and coupling parameters for the mutant forms of 
BsPFK.  The dissociation constants for F6P for T158A, S159A, and H160A are 
comparable to that of wild-type BsPFK.  While the Kia
°  for S159A is almost identical to 
wild-type, T158A shows an almost 2-fold enhanced binding for F6P and H160A shows 
an almost 2-fold diminished binding for F6P.  However, the Kia
°  for T156A is 0.52 ± 
0.005 mM, which is a 17-fold decrease in the substrate binding when compared to wild-
type.  The PEP binding of the mutant BsPFKs is a bit more varied than the F6P binding.  
T156A, S159A, and H160A all exhibit enhanced PEP binding, though to different  
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Figure 3-7  Influence of PEP on K1/2 for F6P of wild-type, T156A, T158A, and S159A 
BsPFKs.  Wild-type is represented by red circles, T156A is represented by purple 
squares, T158A is represented by pink diamonds, and S159A is represented by orange 
triangles.  Solid lines represent the best fit to Equation 3-3. 
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degrees.  Compared to wild-type, S159A and H160A enhance PEP binding by 5- and 15- 
fold, respectively, and T156A enhances the inhibitor binding by 28-fold.  T158A, unlike 
the other variants, exhibits a diminished PEP binding of 0.098 ± 0.004, which is almost a 
2-fold increase compared to that of wild-type.  Considering only the binding 
characteristics of the variant BsPFKs, D12A and T156A BsPFKs are the only two 
mutants that show a significant enhancement in PEP binding while also exhibiting a 
diminished F6P binding. 
The coupling constants of the variants of BsPFK range dramatically depending 
on the mutation.  T158A is the only mutant BsPFK that shows a significant decrease in 
coupling, with a Qax of 0.009 ± 0.0003.  Both S159A and H160A BsPFKs exhibit 
enhanced coupling, when compared to wild-type.  However, the coupling parameter for 
T156A BsPFK is remarkably similar to that of wild-type and D12A BsPFKs.   
Therefore, it appears that the kinetic and coupling parameters of T156A BsPFK compare 
with those of D12A BsPFK, while the parameters for T158A, S159A, and H160A do 
not. 
D12A exhibits a significant decrease in specific activity and shows a dramatic 
effect on the binding of both F6P and PEP without being directly bound to either ligand.  
The unique response of D12A raises some question with regard to the structural integrity 
of the enzyme.  Specifically, has some structural perturbation occurred that could 
explain not only the low activity and poor F6P binding, but also the magnitude of the 
enhanced PEP binding?  Diffraction quality crystals of D12A bound to PEP were 
obtained.  The PEP binding of this mutant is enhanced to such a degree that the 
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indigenous PEP during cell growth (i.e. protein production) stayed bound to the enzyme 
throughout the extensive purification and dialysis processes.  Figure 3-8 shows the 
electron density of PEP in the effector binding pocket of D12A BsPFK.  The crystals 
belong to the space group P212121 with unit cell dimensions of a=96.65, b=112.97, and 
c=131.04.  The asymmetric unit consists of 4 subunits, or one tetramer.  The final 
structure was refined to R-factor/R-free values of 18.86%/23.48% and has a 2.0 Å 
resolution.  Given the kinetic and coupling similarities between D12A BsPFK and 
T156A BsPFK, diffraction quality crystals of T156A BsPFK were obtained.  The crystal 
structure of T156A BsPFK has four PEP molecules bound to the effector binding sites.  
The crystals belong the same space group as PEP bound D12A BsPFK crystals, and the 
unit cell dimensions of T156A BsPFK are a=96.405, b=111.575, and c=129.448.  The 
final structure was refined to R-factor/R-free values of 16.6%/23.78% and has a 2.5 Å 
resolution.  The details describing the diffraction data and refinement statistics are 
displayed in Table 3-1.   
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Figure 3-8  Electron density map showing the electron cloud fitting PEP that is bound in 
the effector binding site in D12A BsPFK. 
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The fact that PEP is bound to the mutant enzymes demonstrates not only the 
extremely tight PEP binding of D12A and T156A BsPFKs, but also that PEP has a small 
dissociation constant.  The purification process included two columns, one of which is a 
strong anion exchange column, as well as numerous dialysis steps.  In order to remove 
the PEP from the D12A BsPFK, the reciprocal binding nature of BsPFK was exploited. 
Specifically, PEP inhibits the binding of F6P; therefore, the binding of F6P must also 
inhibit the binding of PEP to the same degree.  Ligand reciprocity was utilized by 
dialyzing the PEP bound D12A BsPFK in a solution containing F6P for over 48 hours, 
then subsequently removing any substrate from the enzyme by dialyzing for at least 24 
hours in buffer containing no ligand.  Both the PEP bound and the apo D12A BsPFKs 
form stable tetramers, as concluded through comparison to wild-type BsPFK on a native 
gel (data not shown).  Diffraction quality crystals of Apo D12A BsPFK were obtained 
by using the aforementioned dialysis method.  The apo crystals belong to the space 
group P212121 with unit cell dimensions of a=96.05, b=112.66, and c=129.73.  The 
asymmetric unit consists of 4 subunits, or a single tetramer.  The final structure was 
refined to R-factor/R-free values of 20.07%/25.39% and has a 2.3 Å resolution.  The 
details describing the diffraction data and refinement statistics are displayed in Table 3-
1. Several attempts were made to crystallize an apo form of T156A BsPFK.  However, 
every crystal form contained PEP.  This may be attributed to the possibility that PEP 
stabilized the crystal; and if the inhibitor was removed, the enzyme was unstable enough 
not to be able to form a crystal lattice.   
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 There are no significant structural differences between the apo and PEP forms of 
D12A BsPFK, except for a slight deviation in residues K214, H215, and D59.  When the 
available wild-type BsPFK structures (substrate bound, PGA bound, and apo) are 
compared, loop 8-H (residues 213-215) undergoes a hinge motion in response to effector 
binding.  Loop 8-H is open in the apo structure, but closes when ADP is bound and 
closes to a larger extent when PGA is bound.  Figure 3-9 is an overlay of the residues in 
the effector binding site for the apo and PEP structures of D12A BsPFK.  In the PEP 
bound structure of D12A, K214 forms a hydrogen bond with Y69, a hydrogen bond that 
does not exist in the apo version of D12A.  The hydrogen bond formed between K214 
and Y69 pulls K214 out of the binding pocket and causes H215 to tilt towards the CH2 
group of PEP.  The change in the orientation of D59 observed between the apo and 
bound D12A structures is a result of the ligand binding since the same residue overlays 
perfectly with the PGA bound structure of wild-type.   Figure 3-10 is an overlay of the 
effector site residues in the PEP bound D12A structure and in the PGA bound wild-type 
structure.  The positions of the residues are very similar between the inhibitor bound 
proteins except for K214 and H215.  The imidazole ring of H215 is closer to the CH2 
group of PEP in the D12A structure, and in the PGA structure the ring is orientated away 
from the ligand.  The region around the mutation is unaffected by the amino acid 
substitution.  Residues 156-162 (6-F loop) are in the same orientation for apo D12A, 
PEP bound D12A, and PGA bound wild-type.  In addition, the active sites are 
comparable between the three inhibited forms of BsPFK.  Both of the D12A structures 
have undergone the quaternary shift that is characteristic of the inhibited form of BsPFK.   
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Figure 3-9  Overlay of residues in the effector binding site of D12A BsPFK.  Apo D12A 
BsPFK is in black and PEP bound D12A BsPFK is in gray.  PEP is shown in ball and 
stick mode. 
 
 
 
 
 
 
Figure 3-10  Overlay of residues in the effector binding site for inhibitor bound BsPFK.  
Wild-type PGA bound BsPFK in red, with PGA in red and ball and stick mode, and PEP 
bound D12A is in gray with PEP in gray and ball and stick mode. 
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The PEP bound T156A BsPFK crystal structure is similar to the structures of the 
D12A BsPFK enzymes and the PGA bound wild-type enzyme.  Figure 3-2F shows the 
D12 region for the T156A BsPFK crystal structure, which displays the 6-F loop in a 
similar orientation to that of the other inhibitor bound BsPFK crystal structures.  In 
addition, the quaternary structure of T156A BsPFK is similar to that of both D12A and 
PGA bound wild-type BsPFK crystal structures.  Figure 3-11 compares the B-factors for 
the apo D12A (Figure 3-11A), PEP bound D12A (Figure 3-11B), and PEP bound T156A 
(Figure 3-11C) BsPFK crystal structures.  The B-factor, or temperature factor, in protein 
crystal structures is a refinement parameter that describes the fluctuation of an atom 
about its mean position.  B-factors give an estimate of the flexibility of an atom in a 
protein crystal structure; therefore, a large B-factor indicates higher mobility.  
Comparisons of the B-factors for the variant BsPFK crystal structures (Figure 3-11) 
reveal that the structures are remarkably similar to each other, which is not surprising 
given the overall similarity in the structures.  All of the variant enzymes structures 
shown here share similar quaternary structures which resemble that of the PGA-bound 
structure, and they are not as flexible as the substrate-bound form of the enzyme shown 
in Figure 2-3B.  However, none of the variant BsPFK crystal structures are as rigid as 
the PGA-bound enzyme, which is shown in Figure 2-3C.  Overall, when comparing all 
of the BsPFK B-factors, the variant structures resemble the apo BsPFK enzyme the 
most, though they are not exact matches to apo BsPFK. 
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A. B.         
             C.        
Figure 3-11  Comparison of the variant BsPFK B-factors.  (A)  Apo D12A BsPFK  (B) 
PEP-bound D12A BsPFK   (C) PEP-bound T156A BsPFK .  Only monomer A is shown 
for each structure.  PEP is shown as a black space filled molecule.   
  
90 
 
 
The unavailability of an apo form of T156A BsPFK is unfortunate, but not 
detrimental to the overall conclusions that can be drawn from the PEP bound T156A 
BsPFK crystal structure.  When one considers that the quaternary shift causes the 
enzyme to be more favorable for PEP binding, then the fact that T156A BsPFK is bound 
to PEP could imply that the apo form of T156A BsPFK may be in the quaternary shifted 
position as well.   
 
Discussion 
 The model introduced by Schirmer and Evans describing the allosteric nature of 
BsPFK attributes the mechanism of PEP inhibition to the conformational changes  
observed in the enzyme (101).  This proposal is based solely on the structural differences 
observed between two crystal structures of BsPFK, the F6P bound structure and the 
PGA bound structure.  In contrast, the current study, as well as previous studies 
conducted with BsPFK, provides evidence that does not support the proposal made by 
Schirmer and Evans (104-106, 134).  The crystal structure of the apo D12A BsPFK 
shows the enzyme has undergone the quaternary shift; however, analysis of its coupling 
parameters shows that the mutant enzyme exhibits inhibition that is equivalent to that of 
wild-type.  If the quaternary shift was the action for PEP inhibition, then D12A BsPFK 
would not exhibit coupling since the enzyme has adopted the quaternary shift before any 
ligand was added.  In essence, the mutant enzyme would exhibit characteristics similar 
to the wild-type enzyme that had already been saturated by inhibitor.  The Kia
∞ 
(dissociation constant for F6P in the saturating presence of PEP) for wild-type BsPFK is 
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15 mM.  The Kia
°  (dissociation constant for F6P in the absence of PEP) for D12A BsPFK 
is 1.2 mM, which is about 10-fold lower that the Kia
∞ of wild-type.  D12A BsPFK 
exhibits a binding for F6P in the absence of PEP that is comparable to the F6P binding 
of wild-type when in the saturating presence of PEP.  However, even with the poor F6P 
binding D12A BsPFK exhibits, the mutant enzyme still shows heterotropic inhibition on 
par with that of wild-type. 
Given that D12 potentially interacts with multiple residues across the substrate 
interface, each potential interaction was dissected through mutagenesis, kinetic, and 
coupling analysis.  T158 is the only residue across the substrate interface that could 
potentially interact with D12 when the inhibitor is bound to the enzyme and it the only 
potential D12 interaction that is not highly conserved.  T158A is the only mutant enzyme 
tested that showed a significant enhancement in F6P binding and a diminished PEP 
binding.  In addition, T158A is the only mutation that showed a diminished coupling 
parameter.  It is obvious from the kinetic and coupling data discussed here that the 
potential hydrogen bond formed between D12 and T158 when PEP is bound to the 
enzyme is not the interaction that is responsible for the D12A BsPFK binding and 
coupling characteristics. 
 Likewise, the binding characteristics of S159A BsPFK and H160A BsPFK do 
not follow the trends seen with D12A BsPFK.  Whereas, S159A does cause a slight 
enhancement in PEP binding, the F6P binding remains comparable to that of wild-type.  
Also, H160A does enhance PEP binding and diminish F6P binding; however, not nearly 
to the extent that D12A does.  Interestingly, the coupling coefficients for S159A BsPFK 
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and H160A BsPFK show greater inhibition than wild-type.  In fact, the coupling of 
H160A BsPFK is significantly enhanced when compared to wild-type.  Fully saturating 
amounts of F6P and PEP were not achieved, as is evidenced by the lack of points in the 
upper plateau of the K vs. X plot in Figure 3-6 and the high error value for the coupling 
coefficient (Table 3-2).  It may be that H160A BsPFK resembles the apo wild-type 
BsPFK structure since its F6P binding is similar to that of wild-types (Figure 3-6).   All 
crystals grown for H160A BsPFK so far have exhibited low resolution. 
T156 has many similarities with D12.  Both residues are located along the 
substrate binding interface, directly across from each other.  Both residues are 100% 
conserved among all available bacterial ATP-dependent PFK sequences.  Neither residue 
directly binds to a ligand.  In addition, when each residue is replaced by an alanine, the 
coupling and kinetic characteristics are also similar to each other.  D12A and T156A 
enhance PEP binding 100- and 28-fold, respectively and diminish F6P binding 50- and 
17-fold, respectively.  However, the coupling parameters for D12A and T156A are 
remarkably similar to that of wild-type.  
 Caution must be exercised when considering structures alone to describe an 
allosteric mechanism.  Allostery, by its very nature, is a thermodynamic phenomenon 
that is composed of both enthalpic and entropic components.  Structures, though 
insightful, do not address entropic events (dynamics) and should be used as a tool, not 
the basis, for an allosteric mechanism.  In fact, there is growing evidence that proteins 
are dynamic ensembles of conformational states, leading to the idea that all proteins 
have the potential to be allosteric (109).  Accordingly, monomeric and single domain 
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proteins have been shown to be allosteric (109, 110).  Quaternary structure was once 
thought to be a requirement for allostery; however, it may be just a coincidence that 
many allosteric enzymes are oligomeric.  
 The diminished specific activity of D12A BsPFK when compared to wild-type 
BsPFK is a potential complication.  Comparison of the mutant enzymes R252A and 
R252A/D12A to each other reveals that the addition of the D12A mutation did not 
significantly alter the specific activity of the enzyme (125, 134).  The question arises 
whether or not the D12A enzyme intrinsically has a lower specific activity or is a small 
percentage of the total enzyme active?  We are reasonably sure that the D12A enzyme 
forms stable homotetramers, both in the presence and absence of PEP.  Comparison of 
the active sites of the apo D12A and the apo wild-type BsPFKs shows a very small 
perturbation in the orientation of R252.  The D12-R252 interaction, when completely 
removed in the double mutant, may allow for the proper orientation of the substrate in 
the binding pocket.  However, if the negative charge of D12 is removed and the positive 
charge of R252 is unaffected, then the orientation of R252 may hinder the binding of 
F6P.  In order to address this problem, many attempts to produce crystals of D12A 
BsPFK bound to F6P were tried; however, none of them were successful. 
Schirmer and Evans assumed that the PGA BsPFK structure is equivalent to the 
PEP structure, an assumption that can‟t be proven without an actual wild-type PEP 
structure.  However, the PEP bound variants of BsPFK and PGA bound wild-type 
BsPFK structures are very similar.  The structure of the effector binding pockets of the 
PGA bound wild-type BsPFK, apo D12A BsPFK, and the PEP bound variants of BsPFK 
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are analogous.  Therefore, there are no obvious structural explanations to define why 
PEP binds to D12A BsPFK 100-fold tighter and T156A BsPFK 28-fold tighter than 
wild-type.  Structure alone does not consider that the dissociation and coupling constants 
for PGA are not the same as that for PEP in wild-type BsPFK (106).  The differences 
observed in the structures of the substrate bound and the PGA bound wild-type enzymes 
are not sufficient in explaining the mechanism of inhibition in BsPFK.  If structure alone 
did constitute the mechanism for inhibition, then one might predict from the kinetic and 
coupling characteristics of D12A BsPFK that there would be some structural differences 
seen between PEP bound D12A BsPFK, PEP bound T156A BsPFK, and PGA bound 
wild-type BsPFK.  However, there are not any significant differences between the three 
inhibitor bound enzymes.  In other words, there are no obvious differences in the 
effector binding pockets of D12A BsPFK and PGA bound wild-type that would explain 
the large augmentation in PEP binding for the mutant enzyme.   
 We have not uncovered the mechanism for PEP inhibition of BsPFK, but we 
have shown a new possible role for the quaternary shift.  The quaternary shift, 
envisioned at one time as the mechanism for allosteric inhibition of BsPFK, may have a 
significant role in ligand binding.  D12A BsPFK and T156A BsPFK have undergone the 
quaternary shift, exhibit significant changes in ligand binding when compared to wild-
type, and possess coupling constants that are comparable to that of wild-type.  These 
data lead to the idea that the quaternary shift is necessary for ligand binding and not 
heterotropic inhibition.  Further research into the actual dynamics of inhibition of BsPFK 
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must be conducted before a plausible mechanism for allosteric inhibition can be 
proposed. 
 
Conclusion 
 Presented in this paper are the first ever reported PFK crystal structures bound to 
their native inhibitor, PEP.  Whereas, crystal structures of wild-type BsPFK bound to 
PEP have been elusive; D12A BsPFK and T156A BsPFK both exhibit crystal structures 
with PEP bound.  This strong PEP binding is most likely due to the variant enzymes 
possessing the quaternary shifted structure resembling the PGA-bound structure of wild-
type BsPFK.  In addition, D12 and T156 form a strong hydrogen bond across the 
substrate-binding interface that when broken allows the enzyme to undergo the 
quaternary shift.  This quaternary shift most likely enhances the binding of PEP and 
diminishes binding of F6P.  In addition, the quaternary shift appears to have little impact 
on the coupling of BsPFK. 
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CHAPTER IV 
A SOLUTION NMR STUDY OF BACILLUS STEAROTHERMOPHILUS 
PHOSPHOFRUCTOKINASE 
 
The phosphofructokinase (PFK) from the moderate thermophilic prokaryote 
Bacillus stearothermophilus (Bs) is a 136 kDa enzyme that catalyzes the first committed 
step of glycolysis in which the substrates fructose-6-phosphate (F6P) and MgATP are 
converted to fructose-1,6-bisphosphate (F1,6BP) and MgADP.  Researchers have known 
for nearly thirty years that BsPFK is a homotetramer that is allosterically regulated by 
the K-type inhibitor phosphoenolpyruvate (PEP) and the K-type activator MgADP (1, 2).  
Also, both effectors bind to identical binding sites located along one dimer-dimer 
interface, termed the allosteric-binding interface, and the substrate, F6P, binds along the 
other dime-dimer interface, termed the substrate-binding interface.  In 1990, the crystal 
structure of BsPFK bound to phosphoglycolate (PGA), a PEP analog, in all four effector 
sites was compared to the crystal structure of BsPFK bound to F6P and MgADP in all 
four active sites and MgADP in all four effector sites, which will be referred to as the 
“substrate-bound” BsPFK (101).  This comparison revealed that the substrate-bound 
enzyme has undergone a 7° rotation about its substrate-binding interface, termed the 
quaternary shift.  The quaternary shift is accompanied by secondary and tertiary changes 
that include the unwinding of the end of helix 6 and the switching of Arg 162 for Glu 
161 in the F6P binding site. 
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Due to the apparent differences seen between the substrate-bound and the PGA-
bound structures, the allosteric behavior of BsPFK was described using the concerted 
transition model proposed by Monod, Wyman, and Changeux (MWC) (87, 101).  The 
MWC model predicts that allosteric enzymes such as BsPFK exist in equilibrium 
between two states, the tense or, T state, and the relaxed or, R state.  The T state 
represents the inhibitor bound enzyme and the R state represents the substrate bound 
enzyme.  There has been growing kinetic evidence that the MWC model does not 
adequately describe the allosteric behavior of prokaryotic PFK (104, 134, 139).   For 
example, the role of the switching of E161 and R162 in the F6P binding site was 
addressed by Kimmel and Reinhart where they showed, contrary to what was previously 
predicted, that the switching of E161 and R162 in the active sites of the substrate bound 
and PGA bound structures of BsPFK did not adequately explain the allosteric inhibition 
of the enzyme by PEP (104).  In addition, as discussed in Chapter III and contrary to 
what was predicted by the MWC model, the quaternary shift of BsPFK is thought to 
have a substantial role in ligand binding and a lesser role in the allosteric inhibition by 
PEP.  These conclusions were drawn from experiments performed with the variant 
D12A BsPFK.  This single mutation when compared to wild-type BsFPK caused a 100-
fold decrease in the binding affinity for PEP, a 50-fold increase in the binding affinity 
for F6P, but did not alter the coupling constant.  Also, the crystal structure of D12A 
BsPFK indicated that the enzyme had undergone the quaternary shift. 
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 The actions of a K-type inhibitor such as PEP can be quantitatively described by 
a coupling free energy, ∆Gax (94, 95).  The ∆Gax  is expressed in terms of standard free 
energy by the following equation: 
                                                                  ∆Gax= -RTlnQax (4-1) 
where Q
ax
 is the coupling constant for the following dissociation constant: 
                                                                    Q
ax
=
Kia
°
Kia
∞ =
Kix
°
Kix
∞ .                    (4-2) 
Kia
° and Kia
∞ are  the substrate dissociation constants in the absence and saturating 
presence of the effector, respectively, and Kix
°   and Kix
∞ are the effector dissociation 
constants in the absence and saturating presence of the substrate, respectively.  
Therefore, 𝑄𝑎𝑥  describes the following disproportionation equilibrium: 
                                                             XE + EA 
𝑄𝑎𝑥
 XEA + E   (4-3) 
where E is the apo enzyme, XE is the effector bound enzyme, EA is the substrate bound 
enzyme, and XEA is the enzyme bound to both the effector and the substrate 
simultaneously, also called the tertiary complex. 
 The MWC model limits its interpretation of the allosteric behavior of the enzyme 
to the binary complexes on the left side of the disproportionation equilibrium shown 
above, and it doesn‟t acknowledge the tertiary complex or the apo enzyme.  By contrast, 
when kinetic studies are analyzed as described above, all four enzyme forms contribute 
to the value of the coupling constant.  Crystal structures of BsPFK representing the two 
binary complexes were solved in 1981 and 1990 prematurely leading to the proposal of 
the concerted model (101, 121).  As discussed in Chapter III, the apo BsPFK crystal 
99 
 
 
structure was solved, providing a much needed basis for comparison of the changes 
introduced in the formation of each binary complex of BsPFK as well as the first 
structural information pertaining to the right side of the disproportionation equilibrium.  
Also, the apo crystal structure revealed that the unliganded enzyme resembles the 
substrate bound form of BsPFK in many respects.  This result directly disagreed with the 
prediction made earlier by the MWC model (120, 121).  Obtaining structural information 
of the XEA form in which the enzyme is bound to both the inhibitor and the substrate 
simultaneously is the obvious next step in understanding the allosteric mechanism for 
BsPFK.  However, crystallization of XEA have proven to be elusive.  In addition, 
structural data derived from crystal structures offer a static snapshot of the enzyme that 
may be influenced by crystal contacts and the crystallization conditions.  With this in 
mind, methyl TROSY NMR was employed in order to gain more structural information 
about BsPFK in all four states of ligation relevant to the allosteric coupling. 
 Development of novel labeling techniques has opened up the use of NMR to 
study high molecular weight proteins such as aspartate transcarbamoylase (140), 
protease ClpP (141), 20S proteosome (142), and malate synthase G (143).  In the 
following chapter, hetero-nuclear single-quantum coherence (HMQC) experiments were 
conducted with deuterated wild-type and D12A BsPFKs which were specifically labeled 
with δ-13C1H3-isoleucine.  By doing this, only the isoleucines present in the enzymes 
were visualized in chemical shift correlation maps of 
13
C and 
1
H.  Interestingly, there are 
30 isoleucines in one monomer of BsPFK, most of which are well resolved in the NMR 
spectra.  The deuterated and [Ileδ1-13CH3] wild-type BsPFK was exposed to saturating 
100 
 
 
amounts of F6P and PEP, and for the first time solution NMR data are presented that 
depict all four enzyme forms of the disproportionation equilibrium including the elusive 
ternary complex.  NMR spectra show several cross peaks with chemical shifts unique to 
each enzyme form; indicating that each enzyme form takes a different structure.  The 
ternary complex quite interestingly does not resemble either binary complex, but has 
cross peaks with chemical shifts unique to the ternary complex.  D12A BsPFK was 
labeled for NMR experiments because it is known from the crystal structures that the 
variant is in the quaternary shifted position and still undergoes substantial inhibition by 
PEP.  Therefore, we were interested in identifying the peaks that might change when 
PEP and F6P are added, thus causing shifts in cross peaks.  The chemical shift spectra 
for the labeled D12A BsPFK were not as well resolved as the wild-type spectra; 
however, the variant spectra do show promising results.   
 
Materials and Methods 
Materials 
All chemical reagents used in buffers, protein purifications, and enzymatic assays 
were of analytical grade, purchased from Sigma-Aldrich (St. Louis, MO) or Fisher 
Scientific (Fair Lawn, NJ).  Creatine kinase and the ammonium sulfate suspension of 
glycerol-3-phosphate dehydrogenase were purchased from Roche (Indianapolis, IN).  
The ammonium sulfate suspensions of aldolase and triosephosphate isomerase, and the 
sodium salts of phosphocreatine, ATP, and phosphoenolpyruvate were purchased from 
Sigma-Aldrich.  The coupling enzymes in ammonium sulfate suspensions were 
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extensively dialyzed against 50 mM MOPS-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, 
and 0.1 mM EDTA before use.  The sodium salt of F6P was purchased from Sigma-
Aldrich or USB Corporation (Cleveland, OH).  NADH and DTT were purchased from 
Research Products International (Mt. Prospect, IL) and the isotopically labeled materials 
were purchased from Cambridge Isotope laboratories, Inc (Andover, MA).  Mimetic 
Blue 1 resin used for protein purification was purchased from Prometic Biosciences 
(Rockville, MD).  Deionized distilled water was used throughout.  Shigemi NMR tubes 
purchased from Shigemi, Inc. (Allison Park, PA) were used for all NMR experiments.  
Shigemi tubes are specialized NMR tubes that allow for the use of small protein volumes 
around ~300 μl.   
 
Protein Purification of [Ileδ1-13CH3] BsPFK 
The plasmid pBR322/BsPFK (123) contains the gene for BsPFK behind the 
native Bacillus stearothermophilus promoter and was received as a generous gift from 
Simon H. Chang (Louisiana State University).  This plasmid was modified to place the 
BsPFK gene behind an inducible lac promoter in pALTER as described previously 
(126).  Wild-type BsPFK was expressed in  E.coli RL257 cells (124), which is a strain of 
E.coli lacking both the pfkA and pfkB genes.  Protein expression of the deuterated and 
13
C
1
H3-isoleucine labeled BsPFK was performed as described previously by Tugarinov, 
V. et. al., with a few modification (143).  Following transformation, cells were picked 
from a single bacterial colony that was grown on solid Lysogeny Broth (LB)/tet/H2O 
media (Tryptone 10 g/L, yeast extract 5 g/L, and Sodium Chloride 10 g/L, tetracycline 
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12.5 μg/ml).  These cells were transferred to a 5-ml culture of LB/tet/H2O media and 
allowed to grow in a shaking incubator at 37°C until the cell density reaches an OD600 of 
0.7-0.8 (~ 4 hours).  The 5-ml culture was spun down with a speed of 1,200g at room 
temperature and the pellet was very gently resuspended in 1 ml of M9/H2O media (0.048 
M Na2HPO4 (dibasic), 0.022 M KH2PO4 (monobasic), 9 mM NaCl, 19 mM NH4Cl, 0.2 
% Glucose, 2 mM MgSO4, 100 uM CaCl2, 10 ug/ml Thiamine, 10 ug/ml FeSO4, 12.5 
ug/ml Tetracycline) which contained unlabeled glucose and NH4Cl.  Aliquots of the 
resuspension were added to 20 ml of the unlabeled M9/H2O media until the starting 
OD600 was 0.1.  The culture was grown until the OD600 reached 0.6, which took between 
8-10 hours.  The culture was then centrifuged and resuspended in 100 ml of labeled 
M9/D2O media (containing [
2
H,
13
C] glucose and 
15
NH4Cl) so that the beginning OD600 
was 0.1.  These cells were grown until the OD600 was between 0.4-0.5 (4-7 hours), then 
the cells were diluted to 200 ml by the addition of 100 ml labeled M9/D2O media and 
were grown until the OD600
 
reached 0.4-0.5 (2-3 hours).  At this time the culture was 
diluted with labeled M9/D2O media to a volume that equaled 1 L once the α-
ketobutyrate was added and allowed to grow until the OD600 was 0.25 (2-3 hours).  At 
this time, 70 mg/L of [3-
2
H2] ,
13C  α-ketobutyrate was added to the culture.  Following a 
previously established protocol, [3-
1
H],
13C  α-ketobutyrate was deuterated by incubating 
the 
13C α-ketobutyrate at pH 10.5 in D2O for 12-14 hours prior to its addition  (144).  
The pH meter was calibrated with H2O buffers. The culture was allowed to grow for 
approximately one hour until the OD600 was between 0.3-0.4.  Protein expression was 
induced with the addition of 1 mM IPTG and the cells were allowed to grow for no more 
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than 8 hours.  Wild-type BsPFK and D12A BsPFK were expressed as indicated above, 
with the following exceptions:  [
2
H] glucose was the sole carbon source for cells 
expressing wild-type BsPFK and [
2
H] glucose and [
2
H] glycerol were the carbon sources 
for cells expressing D12A BsPFK.   
Cells were centrifuged and frozen at -20°C for at least 12 hours and they were 
resuspended in purification buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0) and 
sonicated in a Fisher 550 Sonic Dismembrator at 0°C in 15 second pulses at setting 6 for 
8 minutes.  The crude lysate was centrifuged using a Beckman model J2-21 centrifuge at 
22,500 x g with a JA-20 rotor for an hour at 4°C.  The clear supernatant was heated at 
70°C for 15 minutes, cooled on ice for 15 minutes, and centrifuged agian for one hour at 
4°C.  The wild-type BsPFK supernatant was diluted 4-fold and loaded onto a Mimetic 
Blue 1 column that was equilibrated with purification buffer.  The column was washed 
with at least 5 bed volumes of purification buffer, and the enzyme was eluted with a 0 – 
1 M NaCl gradient.  The D12A BsPFK supernatant was diluted four-fold and loaded 
onto a DE52 column that was equilibrated with purification buffer.  Enzyme containing 
fractions were pooled and dialyzed into 20 mM Tris-HCl pH 8.5 for wild-type BsPFK 
and 20 mM Tris-HCl pH 7.5 for D12A BsPFK and loaded onto a Pharmacia Mono-Q 
anion exchange column that had been equilibrated with the appropriate buffer. The 
enzymes were eluted with a 0 – 1 M NaCl gradient and PFK containing fractions were 
combined, concentrated, then dialyzed into EPPS Buffer (50 mM EPPS, 10 mM MgCl2, 
100 mM KCl, 0.1 mM EDTA pH 8.0).  Concentrated enzyme was further dialyzed and 
stored in HEPES/D2O Buffer (10 mM deuterated HEPES pH 8.0 (uncorrected), 5 mM 
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MgCl2, 10 mM KCl, and 0.1 mM EDTA) at 4°C.  Apo D12A BsPFK was created 
following the same procedure as described in chapter 2 except HEPES/D2O buffer was 
used instead of EPPS buffer.  The final enzyme was determined to be pure by SDS-
PAGE and the concentration was ascertained using the absorbance at 280 nm (ε = 18910 
M
-1
cm
-1
(126)).  Water was used in all buffers unless D2O is indicated.  The final enzyme 
concentrations achieved for NMR experiments were between 0.4 – 0.5 mM in monomer.  
About 300 μl of protein was added to a Shigemi NMR tube.  F6P and PEP solutions that 
were added to the NMR protein samples were diluted in D2O and were made as 
concentrated as possible in order to add the smallest possible volume.   
 
NMR Spectroscopy 
NMR experiments were performed on a Varian Inova 600 MHz spectrometer, 
using a conventional pulsed-field gradient triple resonance probe.  Two-dimensional 
1
H-
13
C HMQC methyl correlation experiments were acquired on samples of 
15
N, 
2
H, 
[δ13C1H] Ile only wild-type BsPFK (labeled wild-type BsPFK) and 15N, 2H, [δ13C1H] Ile 
only D12A BsPFK (labeled D12A BsPFK) using the pulse schemes described previously 
(145).  A relaxation delay of 2 seconds was used and the total evolution times in the 
1
H 
and 
13
C dimensions were 80 ms and 33 ms, respectively.  The net acquisition time was 
22 hours and the temperature was set to 25°C for all experiments.  NMR data were 
processed and analyzed with nmrPipe(146) and analyzed using Sparky (147).   
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Results 
 Figure 4-1 depicts the apo wild-type BsPFK crystal structure with the thirty 
NMR labeled isoleucines per monomer highlighted.  There is very good coverage of the 
enzyme with isoleucine.  When the apo wild-type BsPFK crystal structure is compared 
to the wild-type substrate bound and PGA bound crystal structures, the regions of the 
enzyme that appear to change the most occur around the ligand binding sites and the 
residues directly around D12, which is discussed in Chapters II and III.  Specific activity 
and ligand binding for the labeled wild-type and D12A enzymes were comparable to 
their unlabeled counterparts, as shown in Table 4-1.  In addition, the activities of the 
labeled enzymes did not diminish over the course of the NMR experiments.  It should be 
noted that an inducible plasmid was necessary to express the proteins in minimal media. 
 The spectra for both the wild-type and mutant enzymes indicate that the protein 
is folded.  The wild-type BsPFK spectra have better dispersion than the D12A spectra; 
however, numerous cross-peaks are very well resolved.  Figure 4-2 shows overlays of 
the chemical shift correlation maps of 
13
C and 
1H of [Ileδ1-13CH3] wild-type BsPFK.  
The comparison is between apo BsPFK, F6P-bound BsPFK, and PEP-bound BsPFK.  
There are several distinct peaks in all three spectra; however, the most significant and 
dramatic differences are seen between the apo and the PEP-bound forms of the enzyme.  
This observation is supported by the solved crystal structures for wild-type BsPFK, 
where the largest structural difference seen is between the apo and PGA bound crystal 
structures.  There are several isoleucines located in and around the regions that undergo 
change; therefore, sensing ligand binding as well as other structural changes should be  
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  A.    B.    C.  
Figure 4-1  Apo BsPFK with the isoleucines highlighted.  There are 30 Ile per monomer, 
each colored yellow, F6P binding residue colored blue, effector binding residue colored 
red.  A) View of individual monomer.  B)  View of tetramer along substrate binding 
interface with the four monomers colored black and gray.  C)  View of tetramer along 
effector binding interface with the four monomers colored black and gray. 
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Table 4-1  Cross-peak coordinates and signal/noise data for unique cross-peaks in NMR 
spectra. 
 
Label 
Cross-peak 
13
C, 
1
H 
(ppm) 
Signal/Noise 
Wt-
Apo 
Wt-
F6P 
Wt-
PEP 
Wt-
F6P/PEP 
D12A-
Apo 
D12A-
F6P 
D12A-
PEP 
A 12.257,    0.666   63    21 
B 13.008,    0.508   64    19 
C 14.216,    1.079   51    15 
D 14.619,    0.987   57    21 
E 
11.149,    0.501  40      
11.125,    0.414    23    
11.195,    0.441      9  
F 
11.149,    0.616  21      
11.132,    0.629      7  
G 
14.871,   1.007     17 11  
14.999,    1.015 40 26      
H 
14.193,    0.593     26 17  
14.200,    0.619 113       
14.188,    0.568  54      
I 
14.300,    0.671  45      
14.500,    0.686   79     
14.400,    0.678      14  
14.449,    0.692       28 
J 
15.908,    0.702 43       
15.915,    0.732  27      
16.169,    0.721   33     
15.937,    0.696    14    
K 10.922,    0.542 52       
L 11.392,    0.647 31       
M 11.253,    0.587    11    
N 14.401,    1.022    15    
O 12.678,    0.846 20 13 24  76 55 140 
P 
14.326,    0.839     43 32  
14.200,    0.835       129 
14.300,    0.862 126 70      
14.400,    0.881   16     
Q 
15.000,    0.920     11   
15.100,    0.920       11 
R 13.711,    0.932     23 36 267 
S 10.978,    0.770     13 10 11 
T 11.325,    0.071     12 8 13 
U 14.449,   0.747      33 25 
V 11.870,    0.767      7 16 
W 0.844,    1.248       13 
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   A.        B.               C. 
 
Figure 4-2  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild-type BsPFK.  A)  Overlay of wild-type apo and 
F6P-bound.  B)  Overlay of wild-type apo and PEP-bound.  C)  Overlay of wild-type F6P-bound and PEP-bound.  Apo is in 
blue, F6P-bound is in green, and PEP-bound is in red.  Cross-peaks are labeled according to Table 4-1. 
O 
I 
E 
F 
D 
C 
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A 
H 
G 
L 
K 
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detectable.  The ternary complex of wild-type BsPFK shown in Figure 4-3 compared to 
apo, F6P-bound, and PEP-bound BsPFK spectra has several cross-peaks that are 
different from the other enzymes. 
Figure 4-4 shows overlays of the chemical shift correlation maps of the variant 
13
C and 
1H [Ileδ1-13CH3] D12A BsPFK, where the apo, F6P-bound, and PEP-bound 
D12A BsPFKs are compared.  Only a few peaks in the D12A BsPFK spectra are 
resolved enough to distinguish any change when ligands bind.  Figure 4-5 shows a 
comparison of the chemical shift correlation maps of the liganded wild-type enzyme 
with the liganded D12A enzyme.  Even with the poor resolution, there are numerous 
peaks that can be concluded to be a result of a particular ligand binding.  There are also 
some peaks that are entirely characteristic of either D12A or wild-type BsPFK. 
 In order to determine if particular cross-peaks were noteworthy in each spectrum, 
all of the spectra were analyzed using Sparky.  Sparky gives precise coordinates, signal 
to noise ratios, and intensity values for each cross-peak.  Through comparing each 
resolvable cross-peak to its counterpart in every NMR sample spectrum, some 
predictions can be made.  Table 4-1 summarizes the coordinates of each interesting 
cross-peak with its signal to noise ratio and which spectrum it occurs in.  In addition, if 
there is not a signal to noise ratio for a particular spectrum, then there was no apparent 
signal for the cross peak in that spectrum.  For example, cross-peaks labeled a, b, c, and 
D are found only in the wild-type-PEP and D12A-PEP bound spectra; therefore, these 
cross-peaks are good indicators for PEP binding.   
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   A.        B.                C. 
 
Figure 4-3  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild-type BsPFK compared with wild-type BsPFK 
ternary complex.  A) Apo and ternary complex.  B) F6P-bound and ternary complex.  C)  PEP-bound and ternary complex.  
Ternary complex is pink, apo is blue, F6P-bound is blue, and PEP-bound is red.  Cross-peaks are labeled according to Table 4-
1. 
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   A.          B.          C. 
 
Figure 4-4  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled D12A BsPFK.  A) Apo and F6P-bound.  B)  Apo and 
PEP-bound.  C)  F6P-bound and PEP-bound.  Apo is in light blue, F6P bound is in gold, and PEP bound is in dark pink.  
Cross-peaks are labeled according to Table 4-1. 
U 
V 
P 
Q 
R 
W 
O 
G 
T 
S 
 
 
 
1
12
 
            
       A.                                B. 
 
Figure 4-5  
13
C-
1
H HMQC spectra of deuterated, Ile-[δ13CH3]-labeled wild-type and D12A BsPFK.  A) F6P-bound wild-type 
(green) and F6P-bound D12A (gold).  B)  PEP bound wild-type (red) and PEP bound D12A (dark pink).  Cross-peaks are 
labeled according to Table 4-1. 
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Cross-peaks labeled E, F, G, and H may be indicative of F6P binding.  Cross-
peak E is in wild-type-F6P bound, wild-type-F6P/PEP bound, and D12A-F6P bound 
spectra at slightly different coordinates; however, there are no definite peaks near these 
coordinates in the other spectra.   This peak appears to be a result of F6P binding; and is 
the only F6P binding cross-peak that appears in the ternary complex.  Cross-peak F does 
not have a similar peak in the ternary complex spectrum; however, it only occurs in the 
F6P bound samples.  Interestingly, peaks G and H are present in both apo and F6P-
bound enzymes and each peak appears to decrease in signal when F6P is added.  Also, 
the cross-peaks for F, G, and H do not exist in the ternary complex.  Cross-peak I is also 
not present in the ternary complex, but it is present in all of the singly liganded spectra 
for both wild-type and D12A enzymes.  In addition, the signal to noise ratio is higher for 
the PEP bound spectra than the F6P spectra.   
Cross-peak J appears only in wild-type spectra while peaks R, S, and T appear 
only in D12A spectra.  The signal to noise ratio for peak R is one of the more prominent 
peaks in the D12A spectra.  Less prominent, but still significant is cross-peak S, which is 
somewhat near peaks in the wild-type apo and wild-type-F6P-bound spectra; however, 
peak T is solely indicative of D12A BsPFK since it is not near any other peak in any 
other spectrum.  Also, peak Q is found only in D12A apo and PEP-bound spectra with 
the same signal to noise ratio in each spectrum.  Cross-peak Q has slightly different 
coordinates in the two spectra, which may be indicative of slight changes that occur 
within the enzyme as a result of further changes in the structure upon PEP binding.  
Cross-peaks U and V are present in the ligand bound spectra of D12A BsPFK; therefore, 
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these peaks may be indicative of ligand binding for D12A BsPFK.  Cross-peak W is 
present only in the PEP bound D12A BsPFK spectra and its chemical shift is far 
removed from the other peaks.  Cross-peak W may be an important indicator of PEP 
binding in D12A BsPFK.  Cross-peaks K and L are found only in the wild-type apo 
spectrum; so they must represent wild-type apo BsPFK.  Cross-peaks M and N are only 
in the ternary complex spectrum.  Interestingly, peak N is located between cross-peaks C 
and D from the wild-type PEP bound spectrum.  Cross-peaks O and P are found in every 
BsPFK spectra except for the ternary complex; so the absence of these peaks are a good 
indicator of the ternary complex.  
 
Discussion 
 The development of transverse relaxation-optimized spectroscopy (TROSY) 
experiments (148) coupled with selective isotope labeling of proteins (149) has allowed 
for the study of increasingly larger macromolecules with NMR spectroscopy.  
Traditionally, using heteronuclear multiple quantum coherence (HMQC) to obtain the 
chemical shifts of hetero-nuclei that are J-coupled in a large protein would give 
correlation maps that are indecipherable.  TROSY is a method that can be attached to 
any experiment and selects only the sharpest doublet component of the signal.  This 
causes half of the signal to be lost; however, it also accounts for a large gain in signal to 
noise ratio which is needed when studying large proteins via NMR.  Applying TROSY-
HMQC experiments to proteins that have been selectively labeled with isotopes accounts 
for the growing amount of NMR experimental evidence of large proteins.  The labeling 
115 
 
 
strategy used for BsPFK involved incorporating isoleucines which were selectively 
protonated at the δ-1 methyl group.  This is simply done by adding α-ketobutyrate, a 
precursor to isoleucine, to the cell culture.  Figure 4-6 shows how [3-
1
H],
13C α-
ketobutyrate, [
12
C, 
2
H] glucose, and 
15
NH4Cl are incorporated into isoleucine, and as a 
result all of the isoleucine residues in the enzyme contain one NMR active methyl group.  
By labeling only the isoleucine residues, very nice coverage of the enzyme was obtained 
along with resolved cross-correlation spectra.  
   
 
 
 
Figure 4-6:  Structure of the α-ketobutyrate precursor added to the minimal media, and 
how each component of the media is incorporated into the end product isoleucine. 
 
 
 
One of the hardest obstacles to overcome when performing any kind of protein 
NMR experiment is to produce large amounts of clean labeled protein.  It was found that 
an inducible promoter for BsPFK is required when growing the cells in M9 minimal 
media.  The Escherichia coli (E. coli) cells used for the expression of BsPFK did not 
contain any native PFK; therefore, the only PFK being produced in the cell would be 
from the plasmid.  And since the carbon source given to the cells was glucose, one 
would expect the use of PFK to be necessary.  However, PFK was not obtained in any 
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noticeable amounts when the non-inducible native Bacillus stearothermophilus promoter 
was used.  It could be that a sufficient amount of PFK was produced to allow 
carbohydrate metabolism to go forward in the cells but not enough to allow for 
detection.  Nevertheless, sufficient quantities of BsPFK were obtained when the 
inducible promoter was used.   
 As discussed in Chapter III, D12A BsPFK, when compared to wild-type, has a 
50-fold diminished F6P binding in the absence of PEP.  However, D12A BsPFK has 
been shown to bind indigenous PEP from the E. coli cell and remain bound to the 
inhibitor through extensive dialysis and affinity column purifications.  When growing 
the labeled NMR D12A BsPFK sample, it became apparent that there was at least a 30% 
reduction in cells when compared to the wild-type BsPFK cells.  The variants enhanced 
PEP binding coupled with diminished F6P binding led the possibility that the cells were 
not able to produce wild-type amounts of PFK due to insufficient quantities of a carbon 
source.  Therefore, in addition to [
2
H] glucose, [
2
H] glycerol was added to the media for 
D12A BsPFK.  Once this was accomplished, the production of D12A BsPFK cells 
matched that of wild-type BsPFK cells. 
 D12A BsPFK spectra show poorer dispersion than wild-type BsPFK spectra.  
This may be due to D12A BsPFK having more flexibility or conformational variability 
in solution than wild-type BsPFK.  The substitution of Asp12 in D12A BsPFK removes 
numerous inter- and intra-subunit interactions; all of which may cause the structure of 
D12A BsPFK to be more variable.  Addition of ligands helped to tighten up some of the 
peaks for D12A BsPFK; however, a larger field instrument is most likely needed to 
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better resolve the cross-peaks for D12A BsPFK.  The resolved cross-peaks of wild-type 
and D12A BsPFK in conjunction with their crystal structures can be used as probes to 
follow the conformation of the enzyme in different liganded states.  Once the peaks for 
D12A BsPFK are better resolved and the peaks are assigned, it may be possible to detect 
precisely which parts of the protein move when PEP and/or F6P bind the enzyme.  Since 
apo D12A BsPFK is already in the quaternary shifted position, it may be possible to 
pinpoint which areas of the enzyme are involved in the allosteric communication 
between PEP and F6P.   
Just as the crystal structures predict, apo wild-type BsPFK NMR spectra are 
similar to that of F6P-bound wild-type BsPFK spectra, whereas PEP-bound BsPFK 
spectra shows a great number of differences when compared with both apo and F6P-
bound BsPFK.  There are enough differences seen between all of the spectra to conclude 
that each enzyme has its own unique structural characteristics.  The ternary complex 
shows several peaks that are distinct and unique to the ternary complex alone, as well as 
some peaks that are present in every spectrum except the ternary complex spectrum.  
Even with the assignment of the peaks being unknown at this point, it is still safe to 
conclude that the ternary complex is indeed unique and different from the other three 
forms of BsPFK.  This is the first structural evidence that supports a F6P-PEP-bound 
BsPFK species and it shows that the ternary complex is not identical to either the 
presumed R or T-state structures.       
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CHAPTER V 
SUMMARY 
 
The two-state model used to describe the allosteric nature of BsPFK was based 
on a comparison between the substrate bound and  PGA bound crystal structures of the 
enzyme, which revealed a conformational change in the PGA bound structure (101).  
This conformational change includes a 7° rotation about the substrate-binding interface, 
termed the quaternary shift.  Additionally, in the substrate-bound form of the enzyme, 
the positively charged R group of R162 interacts with the negatively charged phosphate 
group of F6P, and in the PGA-bound structure, R162 is replaced by the negatively 
charged R group of E161.  The two-state model proposed that these conformational 
changes were the structural basis for the allosteric regulation of BsPFK.  However, a 
previous study performed in the Reinhart Lab proved that the switching of E161 and 
R162 in the active site of the substrate bound and PGA bound structures of BsPFK did 
not adequately explain the allosteric inhibition of the enzyme by PEP (104).  With the 
limited role of E161 and R162 in the allosteric coupling revealed, the role of the 
quaternary shift was still a question.  Therefore, the current study focused on the role of 
the quaternary shift in the allosteric regulation of BsPFK which was addressed through 
the use of X-ray crystallography, NMR spectroscopy, and enzyme kinetics.   
First, the crystal structure for the apo enzyme was determined to 2.8 Å 
resolution.  Contrary to expectations based on the two-state model, we showed that apo 
BsPFK had not undergone the quaternary shift characteristic of the PGA bound 
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structure.  In addition, the apo BsPFK structure provided a true blank slate in which to 
compare all liganded and mutated forms of the enzyme.  A few key residues located in 
the substrate binding and effector binding sites of the apo enzyme were shown to form 
unique and different orientations when compared to the liganded forms of BsPFK.  Now 
the basis for any structural conclusions concerning BsPFK can be made using a 
reference state enzyme form.  The importance of the apo BsPFK crystal structure was 
further emphasized through discussing the coupling free energy of the allosteric 
mechanism.  The free energies of formation for the species for the left hand side of the 
disproportionation equilibrium (Equation 2-3) must equal the free energies of formation 
for the right hand side of the equilibrium.  The two binary forms of BsPFK on the left 
hand side of the equilibrium are represented by the liganded crystal structures of Evans, 
et. al. (101)  And now for the first time the apo BsPFK structure represents a form on the 
right hand side of the equilibrium.  It is very important to note that the crystal structure 
of the ternary complex is still unknown; however, the apo BsPFK crystal structure fills 
an important hole in the structural library of allosterically relevant crystal structures. 
Next, the role of the quaternary structure was investigated using the variants 
D12A BsPFK and T156A BsPFK.  D12 and T156 are noteworthy residues in BsPFK 
because they are located along the substrate binding interface, and they are both 100% 
conserved among 150 prokaryotic ATP-dependent PFKs compared.  Furthermore, D12 
has the potential of interacting with T156, T158, S159, and H160 across the substrate 
binding interface.  When D12 and T156 are mutated to an alanine, both their kinetics and 
structure undergo very interesting changes.  D12A BsPFK, when compared to wild-type 
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BsPFK, has a 50-fold diminished F6P binding and a 100-fold enhancement in PEP 
binding.  T156A BsPFK, when compared to wild-type BsPFK, shows a 30-fold increase 
in PEP binding affinity and a 17-fold decrease in F6P binding affinity.  In addition, 
D12A BsPFK and T156A BsPFK both exhibit a coupling constant that is nearly identical 
to wild-type.  Both the apo and PEP bound crystal structures of D12A BsPFK and the 
PEP bound crystal structure of T156A BsPFK show that the enzymes have undergone 
the quaternary shift and the end of helix 6 has become a loop.  Therefore, D12A BsPFK 
is in the “inhibited” form before PEP every binds to the enzyme, which may explain the 
tighter binding for PEP; however, it does not account for the wild-type coupling 
constant.   
The fact that the quaternary shift has occurred in D12A BsPFK and still exhibits 
PEP inhibition means that the quaternary shift is not central to the coupling of BsPFK.  
In addition, T156A BsPFK possesses very similar kinetic and structural characteristics to 
D12A BsPFK.  To determine if the breaking of the interaction between D12 and T156 is 
causing the unique characteristics of the variants, additional single mutations were made 
near T156 and D12.  Specifically, D12 potentially interacts with T158 across the 
substrate-binding interface when BsPFK is bound to PGA and D12 may interact with 
S159 and H160, in addition to T156, when BsPFK is bound to substrate.  Therefore, 
T158, S159, and H160 were each mutated to an alanine, respectively, and characterized.  
T158A BsPFK was the only variant that showed a slight enhancement in F6P binding, a 
very small decrease in PEP binding, and a diminished coupling when compared to wild-
type.  The variant S159A BsPFK, when compared to wild-type, did not substantially 
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alter the F6P binding, but did enhance both the PEP binding and the coupling.  H160A 
BsPFK diminished the binding for F6P two-fold while enhancing the PEP binding 15-
fold, when compared to wild type.  However, the coupling constant for H160A BsPFK 
demonstrated a very large enhancement when compared to wild-type.  The variants 
T158A BsPFK, S159A BsPFK, and H160A BsPFK did not reveal similar kinetic and 
coupling trends to D12A BsPFK and T156A BsPFK; therefore, these residues must not 
be a major contributor to the strength of the hydrogen bond between D12 and T156.  It is 
concluded that D12 and T156 must form an important hydrogen bond across the 
substrate interface that when broken allows the enzyme to undergo the quaternary shift.  
Thereby, both of the variants that induce the quaternary shift still undergo PEP inhibition 
and substantially alter the binding affinities for the substrate and inhibitor.  In 
conclusion, the role of the quaternary shift appears to be involved in ligand binding, but 
not in the coupling. 
In order to glean additional structural information about wild-type and D12A 
BsPFK, methyl TROSY NMR was employed.  Deuterated and [Ileδ1-13CH3] labeled 
wild-type and D12A BsPFK were prepared so that only the delta methyl group on all of 
the thirty Ile would be detectable by NMR.  HSQC experiments of the labeled enzymes 
were performed with the enzymes exposed to saturating amounts of PEP and F6P.  
Comparison of the wild-type spectra revealed that there are numerous chemical shifts 
that are unique to each form of the enzyme.  The PEP-bound spectrum, when compared 
to the apo spectrum, shows a significant change in chemical shifts.  The F6P-bound 
spectrum is not identical to the apo spectrum, but is much more similar to the apo 
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spectrum than the PEP-bound spectrum.  Interestingly, the spectrum showing the 
enzyme bound to both F6P and PEP simultaneously has several chemical shifts that are 
different from the other wild-type spectra.  These are the first NMR solution structural 
data of the ternary complex in BsPFK.   
The D12A BsPFK methyl TROSY NMR experiments were not as successful as 
the wild-type experiments.  However, even though the chemical shifts were not as well 
resolved as wild-type, there were numerous chemical shifts in the D12A BsPFK spectra 
that indicated ligand binding.   Additional experiments with a higher field spectrometer 
will give better resolution hopefully providing structural information about which parts 
of the enzyme are involved in the PEP inhibition of D12A BsPFK.  Also, a higher field 
instrument will allow for assignment of the Ile residues to be determined.  The chemical 
shift assignments will need to be completed in order to identify which parts of the 
enzyme are moving and to compare to the existing crystal structure. 
In conclusion, the two-state model proposed by Evans, et. al.(101) oversimplifies 
the allosteric mechanism of BsPFK, which is evident from the previous work done by 
Ortigosa, et. al., Kimmel, et. al., and Tlapak-Simmons, et. al.(104, 106, 134, 150) as well 
as the work discussed in the current dissertation.  The structural data presented in 
Chapters II, III, and IV illustrate the verity that BsPFK is capable of more than just two 
structures.  In fact, Chapter II proved through the description of the apo structure of 
BsPFK that the enzyme without any ligands bound is different from the two previously 
solved liganded crystal structures of BsPFK.  The apo BsPFK crystal structure may be 
more like the substrate-bound enzyme, but it must be realized that the structures are not 
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exactly the same.  This is also true for the variant BsPFK crystal structures presented in 
Chapter III, which are more like the PGA-bound structure of BsPFK, but are not exactly 
the same.  In fact, in comparing the quaternary shift of all of the crystal structures, none 
of the newly presented crystal structures have identical quaternary structures to the 
substrate-bound or the PGA-bound enzymes.  The wild-type apo and the variant BsPFKs 
all exhibit quaternary structures that vary by at least one degree from the liganded wild-
type BsPFK quaternary structures.  The structural data support the kinetic data presented 
in Chapter III, emphasizing the fact that the mechanism for the allosteric inhibition of 
BsPFK cannot be easily explained with the crystal structures we currently have 
determined.  The work presented here provides strong evidence that the quaternary 
structure is not central to the allosteric communication between PEP and F6P in BsPFK.  
Through introducing four new crystal structures and the first ever solution NMR data of 
BsPFK we have effectively shown that the structure of BsPFK cannot be delegated to 
just two simple structures.  There are in fact now six unique crystal structures of BsPFK; 
therefore, the two-state model is extremely oversimplified.  The structural, kinetic, and 
coupling data presented in this dissertation demonstrate that the allosteric inhibition of 
BsPFK is much more complicated than previously predicted.  Furthermore, the 
mechanism for PEP inhibition will not be fully understood until we understand the 
energetic and structural characteristics of the ternary complex. 
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